Document:

Filed by Bowne Pure Compliance

 

Exhibit
10.10

LICENSE AGREEMENT

     This License Agreement (“Agreement”) is entered into as of September 1, 2006, by and
between National Quality Care, Inc., a Delaware corporation (“Licensor”), and Xcorporeal,
Inc. (“Licensee”) (each, a
“Party;” collectively, the
“Parties”). The
Parties hereby agree as follows:

1. Defined Terms.

     For purposes of this Agreement, the following definitions will apply:

     “Affiliate” means, when applied to a Party, any entity that is controlled by, controls, or is
under common control with, such Party.

     “Confidential Information” means and includes any non-public information relating to
or concerning a Party hereto (the “Disclosing Party”), or any of its Affiliates, that is
provided or made available to the other Party (the “Receiving Party”), either before or
after the Effective Date of this Agreement, directly or indirectly, in any form whatsoever,
including in writing, orally, and in electronic or other machine readable form, including, but not
be limited to, designs, know-how, inventions, technical data, ideas, uses, processes, methods,
formulae, research and development records and materials, work in process, scientific, engineering
and/or manufacturing records or materials, marketing plans, business plans, financial or personnel
records or materials, present or future products, sales, suppliers, customers, employees, investors
or business, information about this Agreement, and any other non-public business records and
information, the use or disclosure of which might reasonably be construed to be contrary to the
interests of the Disclosing Party or any of its Affiliates, including non-public information of
third parties that is possessed by the Disclosing Party is subject to confidentiality obligations
and that the Disclosing Party is lawfully allowed to disclose to the Receiving Party.

     “Derivative Works” means (a) for Licensor material subject to copyright or mask work
right protection, any work that as a whole represents an original work of authorship, and is based
upon one or more pre-existing works, such as a revision, modification, translation, abridgment,
condensation, expansion, collection, compilation or any other form in which such pre-existing works
may be recast, transformed or adapted; (b) for Licensor patentable materials, any adaptation,
subset, addition, improvement or combination of such materials; (c) for Licensor material subject
to trade secret protection, any new material, information or data relating to and derived from such
material, including new material that may be protectable by copyright, patent or other proprietary
rights; and (d) with respect to each of the above, any material the preparation, use and/or
distribution of which, in the absence of this Agreement or other authorization from Licensor, would
constitute infringement or misappropriation under applicable law.

     “Gross Sales” means the total amount actually received by Licensee as revenue from the
exploitation of the Technology (as defined below) by Licensee, its Affiliates and sub licensees,
collectively, less separately stated freight payable to third parties, commercially reasonable
special packaging, and duties, sales, use, excise, value added and other taxes, discounts, returns,
and allowances.

1

 

     “Intellectual Property Rights” means all of the following worldwide legal rights
owned, held or controlled by Licensor: (a) patents, patent applications, and patent rights; (b)
trademarks, trademark registrations and applications therefor, trade names, rights in trade dress
and packaging; (c) rights associated with works of authorship (including audiovisual works),
including copyrights, copyright applications, and copyright registrations; (d) rights relating to
the protection of trade secrets, confidential information, technical information, know-how, ideas,
concepts, processes, procedures, techniques, discoveries, and inventions; (e) Moral Rights (as
defined below); (f) design rights; (g) rights in name, likeness and other rights of commercial
publicity; (h) any rights analogous to those set forth in the preceding clauses and any other
proprietary rights relating to intangible property; and (i) divisions, continuations, renewals,
reissues, and extensions of the foregoing (as applicable) now existing or hereafter filed, issued,
or acquired.

     “Know-How” means all (i) information and data possessed by Licensor, exclusive of any
of the independent claims contained in the Licensor Patents (but including all other information
and data contained in, or related to, any patent application filed by or on behalf of Licensor),
relating to the exploitation and/or use of the Licensed Products (as defined below), including
without limitation: (a) sources of materials; (b) methods, processes and procedures (and related
test results and design data) for the extraction, isolation, creation, purification, and/or
chemical modification of materials used in the production of the Licensed Products; (c) methods,
processes and procedures used in the design, development, creation, modification, manufacture,
production, processing, storage, packaging, testing and/or evaluation of the Licensed Products,
including without limitation all biological and toxicological tests (and results thereof) together
with all correspondence, notes, memoranda, and other information and/or data provided to, or
received from, all health regulatory authorities; and (ii) trade secrets, data, formulae,
compositions, processes, designs, sketches, photographs, graphs, drawings, samples, program
proposals, presentations, inventions and ideas, past, current, and planned research and
development, current and planned manufacturing or distribution methods and processes, market
studies, business plans, computer software and programs, systems, structures and architectures (and
related processes, formulae, composition, improvements, devices, inventions, discoveries, concepts,
ideas, designs, methods and information), and any other information, however documented, that is
not generally known to the public or that constitutes a trade secret under any applicable trade
secret law.

     “Licensed Products” means all products based on or derived from the Technology (as
defined below), and any products sold in connection with the use of such products, including, but
not limited to the Wearable Kidney and all related devices, whether now-existing or hereafter
developed, that where sold, would infringe or misappropriate one or more of Licensor’s Intellectual
Property Rights or Know-How, including, without limitation, the Licensor Patents or Licensor Patent
Applications.

     “Licensor Patents” means the patents (and all re-issues and extensions) listed
on the Schedule attached hereto and the patents, when issued, based upon the Licensor
Patent Applications and in all divisions, continuations and continuations in part relating
thereto.

2

 

     “Licensor Patent Applications” means the patent applications listed on the
Schedule attached hereto and any substitutions and continuations together with any patent
applications based on, or related to, the Technology that may be filed by Licensor from the date
hereof.

     “Moral Rights” means any rights of paternity or integrity, any right to claim
authorship, to object to or prevent any distortion, mutilation or modification of, or other
derogatory action in relation to the subject work, whether or not such would be prejudicial to the
author’s honor or reputation, to withdraw from circulation or control the publication or
distribution of the subject work, and any similar right, existing under judicial or statutory law
of any country in the world, or under any treaty, regardless of whether or not such right is
denominated or generally referred to as a “moral right.”

     “Net Sales” means Gross Sales less the following: (a) all direct costs and expenses
of Licensee attributable to the research, development, production, marketing, sale and
exploitation of the Licensed Products, including, without limitation, costs of materials and
direct labor costs; and (b) all indirect costs of Licensee properly allocated under generally
accepted accounting principles to the research, development, production, marketing, sale and/or
exploitation of the Licensed Products, including, without limitation, overhead and selling,
general and administrative expenses.

     “Technology” means and includes all existing and hereafter developed Intellectual
Property, Know-How, Licensor Patents, Licensor Patent Applications, Derivative Works, and any
other technology invented, improved or developed by Licensor, or as to which Licensor owns or
holds any rights, arising out of or relating to the research, development, design, manufacture or
use of: (a) any medical device, treatment or method as of the date of this Agreement, (b) any
portable or continuous dialysis methods or devices, specifically including any wearable artificial
kidney, or Wearable Kidney, and related devices, (c) any device, methods or treatments for
congestive heart failure, and (d) any artificial heart or coronary device.

     “Territory” means anywhere in the universe.

2. Grant Of Exclusive License. Subject to Licensee’s continuing full compliance and complete and
timely performance of all of the material obligations, terms and conditions imposed on it by this
Agreement, Licensor hereby grants to Licensee, with right to grant sublicenses, the sole and
exclusive license, during the Term and throughout the Territory, to use. improve, expand and
otherwise exploit the Technology, to make (and have made), use, and sell the Licensed Products,
and otherwise to practice the inventions and the art that is embodied or described in the Licensor
Patents, the Licensor Patent Applications, and any improvements thereto made in whole or in part
by Licensor (whether or not patented) in connection with the
Technology (the “License”), provided, however, that the terms of any sublicense shall expressly conform and be made subject to
the terms and conditions of this Agreement.

3. License Fees, Reports And Records.

     A. License Fees.

          (1) During the Term of this Agreement, Licensee shall pay to Licensor a license fee of
seven percent (7.0 %) of Net Sales (the “Royalty”); provided, however, that

3

 

Licensee shall pay to Licensor a minimum aggregate annual Royalty of two hundred fifty thousand
dollars ($250,000.00) (the “Minimum Royalty”). Within ninety (90) days of each anniversary
of the date of this Agreement, Licensee shall pay Licensor the remaining difference, if any,
between the Minimum Royalty and the aggregate of all Royalty payments for the preceding year. All
payments due hereunder will be paid by wire transfer or check payable in United States currency.
Whenever conversion of payments from any foreign currency is required, such conversion will be made
at the rate of exchange reported in The Wall Street Journal on the last business day of the
applicable reporting period. Unless earlier terminated as provided hereinafter, the obligation of
Licensee to pay Royalties to Licensor shall expire upon the date that none of the Licensed Products
infringe any of the Licensor Patents.

          (2) Notwithstanding the foregoing Section 3(A)(1), in the event that the Merger
Agreement of even date herewith among the Parties and NQCI Acquisition Corporation, a Delaware
corporation (the “Merger Agreement”) is terminated pursuant to Section 6(A) thereof, the
Royalty pursuant to this Agreement will thereafter be as follows:

               (a) If notice of termination is given pursuant to Section 6(A)(3), six and
one-half
percent (6.5%) of Gross Sales;

               (b) If notice of termination is given pursuant to Section 6(A)(1), (5) or
(6), seven
and one-half percent (7.5%) of Gross Sales; and

               (c) If notice of termination is given pursuant to Section 6(A)(2) or (4),
eight and
one-half percent (8.5%) of Gross Sales;

provided, however, that if it is later determined by an arbitrator or court of competent
jurisdiction that a notice of termination was improper, or that the Merger Agreement was
terminated on a different basis or pursuant to a different provision, the Royalty rate will be
retroactively adjusted to the correct rate pursuant to one of the foregoing subsections, and any
difference between the Royalty paid and the Royalty rate determined to be correct will be paid by
the appropriate Party to the other within ninety (90) days of any such final determination.

     B. Reports. Within thirty (30) days following the end of each fiscal quarter,
Licensee shall deliver to Licensor a report setting forth the calculation of the Royalty for the
applicable fiscal period, including the number of Licensed Products sold by Licensee and all
sublicensees (if any), the Gross Sales and Net Sales, as applicable, a reasonable breakdown of
expenses in arriving at the foregoing, any other transactions involving Licensed Products, and the
Gross Sales or Net Sales, as applicable, resulting from all such transactions during such fiscal
quarter, and accompanied by payment of the Royalty due thereon.

     C. Records. Licensee and its sublicensees (if any) shall maintain records of the
transactions involving Licensed Products, Gross Sales, Net Sales, permitted expense deductions,
and all Royalties paid thereon for a period of four (4) years following the end of the quarter
following sale.

          (a) Audits. Licensor may appoint an independent certified public accountant,
who shall have the right to examine the records required under this Section 3.C during
normal business hours on reasonable notice. Licensee shall, as a condition to the grant of any

4

 

sublicense, obtain the agreement of the sublicensee to make such records available for inspection
by Licensor’ independent auditor.

          (b) Audit Expenses. Licensor shall initially bear all costs and expenses of any
audit conducted by Licensor’s independent accountant. If there is an underpayment of Royalties in
excess of five percent (5%), Licensee shall remit the amount of such underpayment to Licensor,
together with a reimbursement for the reasonable costs and expenses of Licensor in connection with
the audit. If there is an overpayment of Royalties in excess of five percent (5%), Licensor shall
remit the amount of such overpayment to Licensee, together with reimbursement for the reasonable
costs and expenses of Licensee in connection with the audit. Any disputes concerning Royalty
amounts due will be resolved by expedited, final offer (baseball style) arbitration.

4. Term.

     A. Term. This Agreement and the License granted hereby shall, subject to all terms and
conditions set forth herein, remain in full force and effect for ninety-nine (99) years from the
date hereof (the “Term”); provided, however, that the Term shall end as to each of the
Licensor Patents and copyrights upon the expiration of the term thereof, and as to each other item
of Intellectual Property Rights when, if and as they cease to be protectible or fall into the
public domain through no fault, action or inaction on the part of either of the Parties.

     B. Termination. Either Party shall have the right to terminate this Agreement: (1) for
uncured material breach of a material term of this Agreement by the other Party, by giving formal
written notice specifying the breach, and such breach has continued without cure for a period of
(a) thirty (30) days after such notice or (b) if the Party receiving such a notice (i) concludes in
good faith that there the conduct alleged to be occurring is not occurring or does not constitute a
material breach of this Agreement, and (ii) timely initiates an arbitration proceeding in
accordance with Section 9.H, thirty (30) days after entry of the arbitration award; or (2)
in the event that the other Party files for protection under the U.S. Bankruptcy Code, or makes an
assignment for the benefit of creditors. Upon termination of this Agreement pursuant to this
Section 4.B, (a) Licensee, and all sublicensees (if any), shall cease to use the Technology
in any way, (b) Licensee, and all sublicensees (if any), shall return to Licensor all Licensor
Confidential Information, and (c) the Parties shall remain liable for all of their respective
obligations under this Agreement that accrued prior to the date of termination.

5. Intellectual Property Rights.

     A. Prosecution of Patent Applications. Licensor shall diligently prosecute all
of the Licensor Patent Applications at its own expense including, without limitation, in those
foreign countries described in the Schedule attached hereto. If, at any time, Licensor
intends to allow any Licensor Patent Application or Licensor Patent to lapse or to become abandoned
or forfeited, Licensor shall notify Licensee, in writing, of its intention at least sixty (60) days
before the date upon which said patent or application is due to lapse or become abandoned or
forfeited. In the event that Licensee desires itself to continue to prosecute any such Licensor
Patent Application, or to take the necessary action to maintain in force any such Licensor Patents,
then Licensee shall, within thirty (30) days following Licensor’s written notice of intent to
abandon, give

5

 

written notice to Licensor of Licensee’s intent to prosecute and/or maintain such patent
rights and Licensor shall thereupon promptly assign the entire right, title and interest, legal and
equitable, in and to that patent or application to Licensee. Licensee shall be under no obligation
to prosecute or maintain in force any Licensor Patents, Licensor Patent Applications or other
Intellectual Property Rights.

     B. Option to Purchase Limited Patent and Intellectual Property Rights. In the event
that Licensor files a petition in Bankruptcy under the U.S. Bankruptcy Code, or has filed against
it a petition of involuntary bankruptcy that is not dismissed with 60 days thereafter, Licensor
will be deemed to have sold to Licensee, the day prior to the filing of said petition, the Licensor
Patents and Licensor Patent Applications and all other Intellectual Property Rights pertaining to
the Technology for a purchase price equal to the amount of the Royalties paid to that time and the
further Royalties that would otherwise have become payable by Licensee to Licensor over the
remainder of the then-current Term of this Agreement. The prospective portion of the purchase price
shall be paid in the same manner and at the same time as the future Royalties would otherwise have
been paid hereunder.

     C. Infringement.

          (1) If Licensor discovers that a third party is manufacturing or selling products in the
Territory that infringe the Licensor Patents or any other legally enforceable Intellectual
Property Rights pertaining to the Technology, it shall notify Licensee of such infringement
and give such Party all appropriate information in its possession relating to the
infringement. This section shall not impose any obligation on either Licensor or Licensee to
maintain any ongoing investigative program to detect any third party infringement.

          (2) Licensee shall have the sole right and authority to take such steps as it deems reasonable
and appropriate in its sole discretion to determine whether actionable infringement is occurring
and, if it is, to stop the infringement in the Territory during the Term, including but not limited
to filing a legal action against the alleged infringer in its own name.

          (3) Licensee shall have the sole right to direct and control the prosecution of such an
action, including selection of counsel and deciding to settle, dismiss or continue the prosecution
of the action on such terms and in the manner it deems reasonable and appropriate in its sole
discretion, and shall, subject to Section 5.C(4), bear all costs and expenses of such
action, and shall retain all damages and other remedies recovered in such action.

          (4) Licensee shall have the right to offset all damages and losses awarded by any Court of
competent jurisdiction relating to any infringement of the Intellectual Property Rights or the sale
or use of the Licensed Products, including Licensee’s legal fees, costs and expenses, against any
Royalty otherwise payable to Licensor.

     D. Development and Expenses.

          (1) Development. Licensee shall make commercially reasonable efforts to develop
and commercially exploit the Technology to generate revenues during the Term.

6

 

          (2) Requested Expenses. Upon Licensee’s request, Licensor shall make commercially
reasonable efforts to continue and advance the research and development program to prepare the
Technology for commercial exploitation, and Licensee shall pay all reasonable and necessary
research and development costs and expenses arising therefrom.

          (3) Monthly Expenses. No later than the earlier of (i) thirty (30) days after the date
on which Licensee has obtained total debt or equity investment of at least three million five
hundred thousand dollars ($3,500,000.00) or (ii) ninety (90) days after the date hereof, Licensee
shall reimburse Licensor’s reasonable and necessary expenses incurred in the ordinary course of
business consistent with past practices (“Licensor
Expenses”), during the period from the date
hereof to the Closing (as defined therein) or termination of the Merger Agreement. All such
Licensor Expenses shall: (a) be only for the specific persons, services and expenses listed in
reasonable detail on the Budget contained in the Company Disclosure Schedule to the Merger
Agreement, (b) be payable hereunder only to the extent not paid pursuant to the Merger Agreement,
(c) be mutually agreed upon in advance of being reimbursed with regard to all Professional Fees set
forth in the Budget, and (d) include, but not be limited to, expenses already paid or accrued
relating to human clinical trials carried out or to be carried out on behalf of Licensor in Italy
and the United Kingdom as set forth in the Budget.

6. Confidentiality.

     A. Each Party agrees that during the performance of this Agreement, it may disclose to the
other Confidential Information of such Disclosing Party. Each Receiving Party shall not, at any
time or in any manner, disclose, copy, modify, distribute or otherwise transfer the Disclosing
Party’s Confidential Information, or any part thereof, to any other person, except as permitted by
this Agreement.

     B. A Receiving Party may disclose Confidential Information (1) to professional advisors of the
Receiving Party in accordance with customary business practices in connection with the Agreement,
and (2) to the Disclosing Party’s employees who have a specific need to know in order to perform
that Party’s obligations hereunder, provided, however, that all such permitted disclosees shall be
required to maintain the confidentiality of the Confidential Information in accordance with this
Agreement, and each Receiving Party shall be responsible for all of its employees’ actions. Each
Party shall use the other Party’s Confidential Information only to properly fulfill its obligations
hereunder, and not for any other purpose. Upon request of a Party, and in any event promptly
following termination of this Agreement under Section 4.C above, each Receiving Party shall
immediately return the originals and all copies of any Confidential Information to the Disclosing
Party.

     C. The obligations and restrictions set forth in this Section 6 shall not apply to any
Confidential Information that falls within any of the following exceptions:

          (1) is or becomes part of the public domain without breach of this Agreement by a Receiving
Party;

          (2) is lawfully in the possession of a Receiving Party prior to receiving it from the
Disclosing Party hereunder;

7

 

          (3) is independently developed by or for a Receiving Party completely apart from the
disclosures hereunder;

          (4) is received from a third party who lawfully acquires such information without
restriction, and without breach of this Agreement by a Receiving Party; or

          (5) is released to the public or to a third party without a duty of
confidentiality, pursuant to a binding court order or government regulation, provided that the
Receiving Party delivers a copy of such order or action to the Disclosing Party and cooperates with
the Disclosing Party if it elects to contest such disclosure.

Nothing provided for in this Section 6 shall be construed to preclude or inhibit Licensee’s
rights to exploit any of its rights under the License.

7. Representations And Warranties.

     A. Representations and Warrants by Licensor. Licensor represents and warrants, as of
the date first set forth above and upon the Effective Date and upon the date each Licensor Patent
issues that:

          (1) Licensor has the right to enter into this Agreement and there are no outstanding
assignments, grants, licenses, encumbrances, obligations or agreements, whether written, oral or
implied, that are inconsistent with this Agreement;

          (2) Licensor is the owner of the entire right, title and interest in and to invention and the
art claimed in the Licensor Patent Applications and the claims contained in any Licensor Patent
Rights that issues and that it has the sole right to grant the licenses granted to Licensee herein;

          (3) The Licensor Patents will not have been fraudulently procured, and Licensor has no reason
to believe that the claims contained in the Licensor Patent Applications will not be issued in a
manner that will protect sales of the Licensed Products in the Territory from competitors utilizing
the invention or its equivalent;

          (4) Licensor has no knowledge of any circumstances that would render the Licensor Patents,
when issued, invalid; and

          (5) Licensor has not granted any license to or under the Technology to any other person or
entity for its use within the Territory.

     B. Representations by Licensee. Licensee represents and warrants that it has the right enter
into and deliver this Agreement and undertake the duties provided for in this Agreement.

8. Indemnification.

     A. Indemnification by Licensor. Licensor agrees to hold harmless, defend
and indemnify each of Licensee and its officers, directors, shareholders, employees, members,

8

 

partners, managers, attorneys and agents, from and against any liability, claims, demands, actions,
costs, expenses, including reasonable attorneys’ fees, or causes of action whatsoever
(collectively, “Claims”) arising on account of:

          (1) Any breach by Licensor of its representations and warranties contained herein;

          (2) Licensee’s lawful and non-negligent use of any Intellectual Property Rights licensed
by Licensor hereunder;

          (3) Any Claims that Licensee’s use of the Intellectual Property Rights in conformity of this
Agreement infringes upon or misappropriates the intellectual property rights of any third party; or

          (4) Licensor’s operations or conduct prior to the date of this Agreement with regard to the
research, development, or production of the Technology and/or Licensed Products. Such Claims shall
include, without limitation, any product liability claims or Claims on account of any injury or
death of persons or damage to property based on alleged defects in the Technology existing as of
the effective date of this Agreement or based on actions or omissions of Licensor, regardless of
whether such Claims are made prior to or at any time after the date of this Agreement.

     B. Indemnification by Licensee. Licensee agrees to hold harmless, defend and
indemnify each of Licensor and its officers, directors, shareholders, employees, members, partners,
managers, attorneys and agents, from and against any Claims arising on account of any breach by
Licensee of it representations and warranties contained herein.

9. General.

     A. Reformation/Severability. If any provision of this Agreement is declared invalid by
any tribunal, then such provision shall be deemed automatically adjusted to the minimum extent
necessary to conform to the requirements for validity as declared at such time and, as so adjusted,
shall be deemed a provision of this Agreement as though originally included herein. In the event
that the provision invalidated is of such a nature that it cannot be so adjusted, the provision
shall be deemed deleted from this Agreement as though such provision had never been included
herein. In either case, the remaining provisions of this Agreement shall remain in effect.

     B. Binding Effect. All of the terms of this Agreement shall be binding upon, and inure
to the benefit of, and be enforceable by, the Parties and their successors and permitted assigns,
if any.

     C. Schedules. All schedules attached hereto and referred to herein, are an integral
part of this Agreement and are incorporated herein by reference hereby.

     D. Subject Headings. The subject headings of the sections of this Agreement are
included solely for purposes of convenience and reference only, and shall not be deemed to

9

 

explain, modify, limit, amplify or aid in the meaning, construction or interpretation of any
of the provisions of this Agreement.

     E. Interpretations and Definitions. In this Agreement whenever the context so
requires, the gender includes the neuter, feminine and masculine and the number includes the
singular and the plural and the words “person” and “party” include individuals, corporations,
partnerships, firms, trusts or associations.

     F. Waiver. Any waiver by any Party of any breach of any term or condition of
this Agreement shall not be deemed a waiver of any other breach of such term or of any other term
or condition, nor shall the failure of any Party to enforce such provision constitute a waiver of
such provision or any other provision, nor shall such action be deemed a waiver or release of the
other Party for any claims arising out of or connected with this Agreement.

     G. Choice of Law. This Agreement and all matters or issues collateral hereto
shall be construed in accordance with, and governed by, the laws of the State of Delaware.

     H. Arbitration. Any dispute, controversy or claim arising out of or relating to
this Agreement, shall be resolved by final and binding arbitration before a retired judge at JAMS
or its successor in Santa Monica, California. The expenses of arbitration, the reasonable fees and
costs of legal counsel, experts, and evidence shall be awarded to the prevailing Party. Any interim
or final award of the arbitrator may be entered in any court of competent jurisdiction.

     I. Successors and Assigns. Neither this Agreement nor any of the rights or
obligations hereunder shall be assignable by any Party hereto without the written consent of the
other Party first obtained and any attempted assignment without such written consent shall be void
and confer no rights upon any third party. Subject to the foregoing, this Agreement shall be
binding upon and shall inure to the benefit of the parties hereto and their respective
representatives, successors and permitted assigns.

     J. No Joint Venture. This Agreement does not constitute and shall not be
construed to constitute an agency, a partnership or a joint venture between the Parties. Neither
Party shall have any power or right, nor shall it represent itself as having any power or right to
obligate or bind the other Party in any manner whatsoever and nothing contained in this Agreement
shall give or is intended to give any rights of any nature to third party. This is an agreement
between separate entities and neither is the agent of the other for any purpose whatsoever.

     K. Notice. All written notices or other written communications required under
this Agreement shall be deemed properly given when provided to the parties entitled thereto by
personal delivery (including delivery by commercial services such as messengers and airfreight
forwarders), by electronic means (such as by electronic mail, telex or facsimile transmission) or
by mail sent registered or certified mail, postage prepaid at the following addresses (or to such
other address of a Party designated in writing by such Party to the others):

If to Licensee:

Xcorporeal, Inc.
 Attn:
Terren S. Peizer

10

 

c/o Greenberg Traurig, LLP

2450 Colorado Avenue, Suite 400E

Santa Monica, California 90404

Attn: John C. Kirkland, Esq.
 Fax: (310) 586-0286

With a copy to:

Greenberg Traurig, LLP
 2450 Colorado
Avenue, Suite 400E
 Santa Monica,
California 90404
 Attn: John C.
Kirkland, Esq.
 Fax: (310)586-0286

If to Licensor:

National Quality Care, Inc.

9033 Wilshire Boulevard, Suite 501

Beverly Hills, California 90211

Attention: Robert M. Snukal

Fax: (310) 840-5681

With a copy to:

Jenkins & Gilchrist, LLP

12100 Wilshire Boulevard, 15th Floor

Los Angeles, California 90025

Attn: Jeffrey P. Berg, Esq.

Fax: (310) 820-8859

All notices given by electronic means shall be confirmed by delivering to the Party entitled
thereto a copy of said notice by certified or registered mail, postage prepaid, return receipt
requested. All written notices shall be deemed delivered and properly received upon the earlier of
two (2) days after mailing the confirmation notice or upon actual receipt of the notice provided by
personal delivery or electronic means.

     L. Further Documents. Each Party shall execute and deliver, at any time and
from time to time, upon the request of the other such further instruments, papers or documents as
may be necessary or appropriate to consummate the transactions contemplated hereby and to take such
other action as the other Party may reasonably request to effectuate the purposes of this
Agreement.

     M. Amendment. This Agreement may only be amended, modified or changed by a
written document executed by both Parties.

11

 

     N. Counterparts. This Agreement may be executed in one or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument.

     O. Entire Agreement. This instrument contains the entire agreement between the
Parties, and supersedes all prior or contemporaneous understandings or agreements, whether
written or oral. Neither Party has relied upon any promise, representation or undertaking not
expressly set forth herein.

     IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the day
and date first set forth above.

LICENSOR:

NATIONAL QUALITY CARE, INC.

	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Victor Gura	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	Name: Victor Gura, M.D.	 	 	 	 	 	 
	Title: Chief Scientific Officer	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Robert M. Snukal	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	Name: Robert M. Snukal	 	 	 	 	 	 
	Title: Chief Executive Officer	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	 	 	LICENSEE:	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	 	 	XCORPOREAL, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	By:
	 	/s/ Terren S. Peizer
	 	 
	 

	 	 	 	 	 	 	 	 
	 	 	 	 	Name: Terren S. Peizer	 	 
	 	 	 	 	Title: Chairman of the Board	 	 

12Filed by Bowne Pure Compliance

 

MERGER
AGREEMENT

Exhibit
10.11

     This Merger Agreement (“Agreement”) is entered into as of September 1, 2006, by
and among Xcorporeal, Inc. (“Shell”), NQCI Acquisition Corporation, a Delaware corporation
and a newly-created wholly-owned Subsidiary of Shell (“Merger Subsidiary”), and National
Quality Care, Inc., a Delaware corporation
(“Company”), (each a “Party” and
collectively the “Parties”).

RECITALS

     A. This Agreement contemplates a reverse triangular merger as defined in Section 368(a)(2)(E)
of the Code of Merger Subsidiary with and into Company in a transaction qualifying as a
reorganization under Section 354 of the Code.

     B. This Agreement further contemplates that, in the event that the merger transaction
does not close, Company may assign its Technology to Shell in consideration of Shell Shares.

     C. The Closing of the transactions contemplated by this Agreement are subject to the filing
and effectiveness of a Registration Statement and Information Statements as set forth herein.

     D. At the Closing, either the Company Stockholders will receive Shell Shares in exchange for
their Company Shares, and the Company will become a wholly-owned Subsidiary of Shell, or the
Company will receive Shell Shares in consideration of the Technology Transaction.

     NOW, THEREFORE, in consideration of the premises and the representations, warranties and
covenants contained herein, the Parties agree as follows.

1. Basic Transaction.

     A. Merger. On and subject to the terms and conditions of this Agreement,
Merger Subsidiary will merge with and into Company (the “Merger”). Company will be the
corporation surviving the Merger (after the Closing, the “Surviving Corporation”). The
separate corporate existence of Merger Subsidiary will cease as of the Merger.

     B Technology Transaction. If the Merger is terminated before the Closing of the
Merger in accordance with Section 6.A, the Closing of the Technology Transaction shall
proceed in accordance with Section 6.B.

     C. Documents. As soon as practicable following the execution of this Agreement, each
Party will deliver to the others the various certificates, instruments, and documents referred to
herein.

     D. Closing. The closing of one of the two mutually-exclusive transactions contemplated
by this Agreement, either in the form of the Merger or the Technology Transaction,

 

 

will take place as soon as practicable on the business day following the satisfaction or
waiver of all conditions to the obligations of the Parties to consummate the transaction, other
than conditions with respect to actions the respective Parties will take at the Closing itself, or
such other time as the Parties may mutually determine, (the “Closing”).

     D. Voting Agreements.

          (1) Stockholder Agreement. Concurrently herewith, each of the Majority Stockholders
will enter into the Voting Agreement (the “Stockholder Agreement”), in the form attached as
Exhibit A hereto, absolutely and irrevocably ratifying, approving and consenting to: (a)
the License Agreement between Company and Shell entered into concurrently herewith (the
“License Agreement”) and (b) subject to Sections 2.B(7) and 3.J and
effective as of the Closing, this Agreement and the transactions contemplated by this Agreement,
including without limitation the Merger or the Technology Transaction.

          (2) CNL Agreement. Concurrently herewith, CNL will enter into the Agreement (the
“CNL Agreement”), in the form attached as Exhibit B hereto (together with the
Stockholder Agreements, the “Voting Agreements”), absolutely and irrevocably ratifying,
approving and consenting to: (a) the License Agreement; and (b) subject to Sections 2.A and
3.J and effective as of the Closing, this Agreement and the transactions contemplated by
this Agreement, including without limitation the Merger or the Technology Transaction.

          (3) Director Agreement. Concurrently herewith, Shell will enter into the
agreement (the “Director Agreement”), in the form attached as Exhibit C
hereto.,

     E. Merger Certificate. At the Closing of the Merger, Shell will file with the
Secretary of State of the State of Delaware a Certificate of Merger between Company and Merger
Subsidiary, in the form attached hereto as
Exhibit D (the “Merger Certificate”).

     F. Effect of Merger or Technology Transaction.

          (1) General. The Merger will become effective upon filing of the Merger Certificate
with the Secretary of State of the State of Delaware (the “Effective Time”). The Merger
will have the effect set forth in the DGCL. The Surviving Corporation may, at any time after the
Closing, take any action, including executing or delivering any document, in the name and on behalf
of either Company or Merger Subsidiary in order to carry out and effectuate the transactions
contemplated by this Agreement.

          (2) Certificate of Incorporation. The certificate of incorporation of Surviving
Corporation will be amended and restated at and as of the Closing to read as did the certificate of
incorporation of Merger Subsidiary immediately prior to the Closing, except that the name of
Surviving Corporation may be changed by Shell.

          (3) Bylaws. The bylaws of Surviving Corporation will be amended and restated at and as
of the Closing to read as did the bylaws of Merger Subsidiary immediately prior to the Closing,
except that the name of Surviving Corporation may be changed by Shell.

2

 

          (4) Directors. The directors of Company who shall be directors of Surviving
Corporation at and as of the Closing are as set forth in the attached Exhibit E.

          (5) Conversion of Company Securities.

               (a) Conversion of Shares. At and as of the Closing of the Merger, (a) all issued
and
outstanding Company Securities (other than any Dissenting Shares) will, by virtue of the Merger and
without any further action on behalf of Shell, Company or any Company Stockholder, automatically be
converted into and become validly issued, fully paid and non assessable Shell Shares (the ratio of
Company Shares to one (1) Shell Share is referred to herein as
the “Conversion Ratio”),
such that all holders of all Company Shares will collectively receive, on a fully diluted basis,
after taking into account the conversion into Company Shares of all Convertible Debt, which shall
occur prior to and as a condition of Closing, an aggregate of forty-eight (48%) of all Shell Shares
outstanding as of the date hereof, adjusted for any stock splits or dividends prior to the Closing,
(b) each Dissenting Share will be converted into the right to receive payment from Surviving
Corporation with respect thereto in accordance with the provisions of the DGCL and, to the extent
applicable, the CGCL, and (c) all unissued and treasury Company Shares will be cancelled.

               (b) Share Certificates.

                    (i) Following the Closing of the Merger, upon surrender of an
original stock certificate representing Company Shares, Shell will cause to be issued a stock
certificate for Shell Shares to which such Person is entitled pursuant to the Conversion Ratio,
bearing any necessary or appropriate restrictive legend. Shell will not pay any dividend or make
any distribution on Shell Shares with a record date at or after the Closing to any record holder of
outstanding Company Shares until the holder surrenders for exchange his, her, or its certificates
that represented Company Shares.

                    (ii) If any certificate evidencing Shares shall has been lost,
stolen or destroyed, upon the making of an affidavit of that fact by the Person claiming the
certificate to be lost, stolen or destroyed and, if required by Shell or its Transfer Agent, the
posting of an indemnity bond, in such reasonable amount as the Transfer Agent may direct, as
collateral security against any claim that may be made with respect to the certificate, Shell will
cause to be issued in exchange for the lost, stolen or destroyed certificate the applicable number
of Shell Shares.

               (c) Conversion of Warrants. All warrants to purchase Company
Shares issued and outstanding at the Closing of the Merger, as set forth in the attached
Exhibit F (“Company Warrants”) will, by virtue of the Merger and without any action
on the part of Shell, Company or the holders of the Warrants, be converted into and will become
warrants to purchase Shell Shares (“Shell Warrants”) as part of the Conversion Ratio, on
the same terms and conditions as those set forth in Exhibit F.

               (d) Conversion of Options. All options to purchase Company Shares outstanding at the
Closing of the Merger, as set forth in the attached Exhibit G (“Company

3

 

Options”) will, by virtue of the Merger and without any action on the part of Shell,
Company or the holders of the options, be assumed by Shell, and will become options to purchase
Shell Shares (“Shell Options”) as part of the Conversion Ratio, on the same terms and
conditions as those set forth in Exhibit G.

               (e) No fractional Shell Shares, or Shell Warrants or Shell Options to receive fractional
Shell
Shares will be issued, and any right to receive a fractional share will be rounded to the nearest
whole Shell Share. As of the Closing of the Merger, the Company Shares, Company Warrants and
Company Options (collectively, “Company Securities”) will be deemed canceled and will cease
to exist, and each holder of a Company Security will cease to have any rights with respect thereto,
other than those expressly set forth in this Section l.F(5). After the Closing of the
Merger, transfers of Company Shares outstanding prior to the Closing will not be made on the stock
transfer books of Surviving Corporation.

               (f) CNL Warrants. At the Closing of the Merger, CNL will be granted Shell Warrants to
purchase a number of validly issued, fully paid and non-assessable Shell Shares equal to the
aggregate number of Shell Shares into which any Company Warrants outstanding as of the Closing are
convertible, at prices per share equal to the prices per share of all such Company Warrants, and
otherwise on terms equal to or better than the most favorable terms of such Company Warrants;
provided, however, that the Shell Warrants granted to CNL pursuant to this Section
l.F(5)(f) may be exercised only when the corresponding number of such converted Company
Warrants are exercised.

               (g) CNL Options. At the Closing of the Merger, CNL will be granted Shell Options to
purchase a number of validly issued, fully paid and non-assessable Shell Shares equal to the
aggregate number of Shell Shares into which any Company Options outstanding as of the Closing are
convertible, at prices per share equal to the prices per share of all such Company Options, and
otherwise on terms equal to or better than the most favorable terms of such Company Options;
provided, however, that the Shell Options granted to CNL pursuant to this Section l.F(5)(g)
may be exercised only when the corresponding number of such converted Company Options are
exercised.

               (h) Technology Shares. At the Closing of the Technology Transaction, Shell shall
issue and deliver to the Company the number of Shell Shares set forth in Section 6.B(2).

2. Conditions To Obligations To Close.

     A. Conditions to Shell’s Obligation. The obligation of each of Shell and, in the case
of the closing of the Merger, Merger Subsidiary to consummate the transactions to be performed by
it in connection with the Closing is subject to satisfaction of the following conditions:

          (1) The representations and warranties set forth in Section 4 will be true and
correct in all material respects as if made at and as of the Closing, except to the extent that
such representations and warranties are qualified by the term “material,” or contain terms such as
“Adverse Effect” or “Adverse Change,” in which case such representations and warranties as so

4

 

written, including the term “material” or “Material,” will be true and correct in all
respects at and as of the Closing;

          (2) Company will have performed and complied with all of its covenants hereunder in all
material respects through the Closing, except to the extent that such covenants are qualified by
the term “material,” or contain terms such as “Adverse Effect” or “Adverse Change,” in which case
Company will have performed and complied with all of such covenants as so written, including the
term “material” or “Material,” in all respects through the Closing;

          (3) There will not be any judgment, order, decree or injunction in effect that would (a)
prevent consummation of any of the transactions contemplated by this Agreement, (b) cause any of
the transactions contemplated by this Agreement to be rescinded following consummation, (c)
adversely affect the right of Shell to own the capital stock of Surviving Corporation and to
control Surviving Corporation and its Subsidiaries, or (d) adversely affect the right of any of
Surviving Corporation and its Subsidiaries to own its assets and to operate its business;

          (4) Company will have delivered to Shell a certificate to the effect that each of the
conditions specified in Sections 2.A(l)-(3) is satisfied in all respects;

          (5) In the case of the Closing of the Merger, Company will have delivered to Shell an executed
counterpart of the Merger Certificate;

          (6) Shell will have received from counsel to Company an opinion in form and substance as set
forth in Exhibit H attached hereto;

          (7) At least twenty (20) calendar days will have passed since a definitive written information
statement pursuant to Rule 14c-2 under the Exchange Act (“Company Statement”), which will
include the information required to be disclosed under Rule 14f-l under the Exchange Act, has been
filed with the SEC and transmitted to every record holder of Company Shares from whom proxy
authorization or consent is not solicited;

          (8) At least twenty (20) calendar days will have passed since a definitive written information
statement pursuant to Rule 14c-2 under the Exchange Act (“Shell Statement”) has been filed
with the SEC and transmitted to every record holder of Company Shares from whom proxy authorization
or consent is not solicited;

          (9) In the case of the Closing of the Merger, a registration statement relating to the
offering and issuance of the Shell Shares (“Registration Statement”) will have become
effective under the Securities Act, and no stop order suspending the effectiveness of the
Registration Statement or any part thereof shall have been issued and no proceeding for that
purpose, and no similar proceeding in respect of the Company Statement shall have been initiated or
threatened in writing by the SEC or any other Governmental Authority; and all requests for
additional information on the part of the SEC or any other Governmental Authority shall have been
complied with to the reasonable satisfaction of the parties hereto, or an exemption from the
Securities Act and applicable state securities laws is available;

5

 

          (10) In the case of the Closing of the Merger, all of Company’s debt securities that give the
holder of such debt security the right to purchase a specified number of Company Shares
(“Convertible Debt”), as set forth in Exhibit J, shall have been converted to
Company Shares as part of the Conversion Ratio. All other Company debt obligations shall have been
either retired by Company or converted to Company Shares prior to the Closing;

          (11) In the case of the Closing of the Merger, Shell will have received the resignations,
effective as of the Closing, of each director and officer of Company and its Subsidiaries,
other than those set forth in Exhibit E attached hereto;

          (12) As of the date of execution of this Agreement, Company shall have obtained an executed
Affiliate Agreement in the form of Exhibit I
hereto (the “Affiliate Agreement”)
from all Persons who may be deemed to be an “Affiliate” of Company within the meaning of Rule 145
promulgated under the Securities Act, as listed on Section 2.A(11) of the Company
Disclosure Schedule. Shell shall be entitled to place legends, as specified in the Affiliate
Agreement, on the certificates evidencing the Shell Shares to be received by any Affiliate of
Company and to issue appropriate stop transfer instructions to the transfer agent for such Shell
Shares consistent with the terms of the Affiliate Agreement, regardless of whether such Person has
executed an Affiliate Agreement;

          (13) As of the date of execution of this Agreement, Company, Shell, CNL and each of the
Majority Stockholders shall have entered into the Voting Agreements;

          (14) In the case of the Closing of the Merger, prior to the Closing the Parties and the
Directors named therein shall have executed an Asset Assignment and Debt Payment Agreement (the
“AADP Agreement”), in the form attached as Exhibit J hereto, pursuant to which,
among other provisions, LACD shall have assumed all of Company’s accounts payable and accounts
receivable which, together with LACD’s liabilities, accounts payable and accounts receivable, shall
be disclosed to Shell in writing within thirty (30) days of the date hereof;

          (15) In the case of the Closing of the Merger, prior to the Closing Company shall have sold
all assets of Los Angeles Community Dialysis, Inc., a California corporation and wholly-owned
Subsidiary of Company (“LACD”), with the exception of LACD’s accounts receivable, and LACD
shall have no outstanding liabilities of any kind except as scheduled in the AADP Agreement;

          (16) The Parties shall have executed the License Agreement; and

          (17) This Agreement shall have been adopted by the requisite vote of the stockholders of
each of Shell, and, if required, Merger Sub, and Company.

Shell and Merger Subsidiary may waive any condition specified in this Section 2.A if it or
they execute a writing so stating at or prior to the Closing.

     B. Conditions to Company’s Obligation. The obligation of Company to consummate
the transactions to be performed by it in connection with the Closing is subject to satisfaction of
the following conditions:

6

 

          (1) The representations and warranties set forth in Section 5 will be true and correct
in all material respects at and as of the Closing, except to the extent that such representations
and warranties are qualified by the term “material,” or contain terms such as “Adverse Effect” or
“Adverse Change,” in which case such representations and warranties as so written, including the
term “material” or “Material,” will be true and correct in all respects at and as of the Closing;

          (2) Each of Shell and, in the case of the Closing of the Merger, Merger Subsidiary will have
performed and complied with all of its covenants hereunder in all material respects through the
Closing, except to the extent that such covenants are qualified by the term “material,” or contain
terms such as “Adverse Effect” or “Adverse Change,” in which case Shell and, in the case of the
Closing of the Merger, Merger Subsidiary will have performed and complied with all of such
covenants as so written, including the term “material” or “Material,” in all respects through the
Closing;

          (3) There will not be any judgment, order, decree or injunction in effect that would (a)
prevent consummation of any of the transactions contemplated by this Agreement, or (b) cause any of
the transactions contemplated by this Agreement to be rescinded following consummation;

          (4) Shell will have delivered to Company a certificate to the effect that each of the
conditions specified in Sections 2.B(1)-(3) is satisfied in all respects;

          (5) In the case of the Closing of the Merger, Shell will have delivered to Company an
executed counterpart of the Merger Certificate;

          (6) Company will have received from counsel to Merger Subsidiary an opinion in form and
substance as set forth in Exhibit K attached hereto.

          (7) At least twenty (20) calendar days will have passed since the Company Statement has been
filed with the SEC and transmitted to every record holder of Company Shares from whom proxy
authorization or consent is not solicited;

          (8) The Registration Statement will have become effective under the Securities Act, or an
exemption from the Securities Act and applicable state securities laws is available;

          (9) At least twenty (20) calendar days will have passed since the Shell Statement, if required
under applicable law, has been filed with the SEC and transmitted to every record holder of Shell
Shares from whom proxy authorization or consent is not solicited;

          (10) As of the date of execution of this Agreement, CNL shall have entered into the CNL
Agreement;

          (11) The Parties shall have executed the License Agreement;

7

 

          (12) In the case of the Closing of the Merger, prior to the Closing the Parties shall have
executed the AADP Agreement;

          (13) This Agreement shall have been adopted by the requisite vote of the stockholders of each
of Shell and Merger Sub, if required; and

          (14) The Parties shall have executed the Director Agreement.

Company may waive any condition specified in this Section 2.B if it executes a writing so
stating at or prior to the Closing.

3. Covenants.

     The Parties agree as follows with respect to the period from and after the execution of
this Agreement until the Closing or termination of this Agreement:

     A. General. Each of the Parties will use its best efforts to prepare, execute and
deliver all documents, take all actions and do all things necessary, proper, or advisable in order
to consummate and make effective the transactions contemplated by this Agreement as soon as
practicable, including the satisfaction, but not waiver, of all of the Closing conditions set forth
in Section 2.

     B. Notices. Company will give any notices (and will cause each of its Subsidiaries to
give any notices) to third parties, and will use its best efforts to obtain (and will cause each of
its Subsidiaries to use its best efforts to obtain) any necessary third-party consents.

     C. SEC and State Filings. Each of the Parties will, and will cause each of its
Subsidiaries to, give any notices to, make any filings with, and use its best efforts to obtain any
authorizations, consents, and approvals of Governmental Authorities in connection with the matters
referred to herein. Without limiting the generality of the foregoing:

          (1) Company Statements. Company and Shell, if required, will prepare as soon as
practicable and timely file with the SEC preliminary and definitive Company Statements, in form and
substance reasonably satisfactory to Shell and Company, respectively, and mail all necessary and
appropriate definitive documents to all Company Stockholders and Shell Stockholders, respectively,
and as soon as practicable after approval by the SEC or the expiration of applicable waiting
periods.

          (2) Registration Statement. Shell will prepare as soon as practicable and timely file
with the SEC the Registration Statement on appropriate form with respect to the Merger or the
Technology Transaction, as the case may be, and the offering of the Shell Shares. Within ninety
(90) days following the effectiveness of a resale registration statement on Form S- 3 on behalf of
selling stockholder from whom Shell has raised in excess of twenty-five million dollars
($25,000,000.00), Shell will: (a) prepare and file with the SEC a registration statement on Form
S-3, with respect to any unregistered Shell Shares (i) underlying the Shell Warrants and Shell
Options or (ii) issued in connection with the Technology Transfer; and (b) use reasonable

8

 

efforts to cause such registration statement to become and remain effective for a period of five
(5) years following the Closing.

          (3) Blue Sky Filings. Shell will take all actions that may be necessary, proper, or
advisable under applicable state securities laws in connection with the offering and issuance of
the Shell Shares.

          (4) Further Cooperation. The filing Party in each instance will use its best efforts
to respond to the comments of the SEC or any state Governmental Authorities on any filings and will
make any further filings, including amendments and supplements, in connection therewith that may be
necessary, proper, or advisable. Shell will provide Company, and Company will provide Shell, with
whatever information and assistance in connection with the foregoing filings the filing Party may
request.

     D. Section 16 Matters. Prior to Closing of the Merger, the Board of Directors of
Company will adopt a resolution consistent with the interpretive guidance of the SEC stating that
the disposition of Company Shares, Warrants or Options pursuant to this Agreement by any officer or
director of the Company who is a covered person for purposes of Section 16 of the Exchange Act
(together with the rules and regulations thereunder, “Section 16”) (each, a “Company CoveredPerson”) is intended to be an exempt transaction for purposes of Section 16 provided that such
Company Shares, Warrants or Options are listed in the Section 16 Information (as defined below).
Company shall deliver to Shell such Section 16 Information in a timely fashion prior to Closing.
Upon receiving Company’s Section 16 Information and prior to Closing, the Board of Directors of
Shell will adopt a resolution consistent with the interpretive guidance of the SEC stating that the
acquisition of Shell Shares, Warrants or Options pursuant to this Agreement by any Company Covered
Person who becomes a covered person of Shell for purposes of Section 16 is intended to be an exempt
transaction for the purposes of Section 16 provided that such Shell Shares, Warrants or Options are
listed in the Section 16 Information. “Section 16 Information” shall mean information
accurate in all material respects regarding the Company Covered Persons and the number of Company
Shares held by each Company Covered Person that are to be exchanged for Shell Shares pursuant to
this Agreement, and the number and description of the Company Warrants and Options held by each
such Company Covered Person which are to be converted into Shell Warrants and Options hereunder.

     E. Operation of Business. Company will not (and will not cause or permit any of its
Subsidiaries to) engage in any practice, take any action, or enter into any transaction outside the
Ordinary Course of Business. Without limiting the generality of the foregoing, without the prior
written consent of Shell, neither Company nor any of its Subsidiaries will:

          (1) Authorize or effect any change in its charter or bylaws;

          (2) Grant any options, warrants, or other rights to purchase or obtain any of its stock or
issue, sell, or otherwise dispose of any of its capital stock (except upon the conversion or
exercise of options, warrants, and other rights currently outstanding);

9

 

          (3) Declare, set aside, or pay any dividend or distribution with respect to its stock (whether
in cash or in kind), or redeem, repurchase, or otherwise acquire any of its capital stock;

          (4) Issue any note, bond, or other debt security or create, incur, assume, or guarantee any
indebtedness for borrowed money or capitalized lease obligation outside the Ordinary Course of
Business; provided, however, that Company may issue Convertible Debt to any of its directors and
officers so long as such Convertible Debt is converted to Company Shares prior to Closing in
accordance with Section 2.A(9) hereof, and that the Conversion Ratio will be automatically
adjusted to take into account any additional Company Shares resulting therefrom so that the total
number of Shell Shares issued in exchange for Company Shares will not be increased;

          (5) Make any capital investment in, make any loan to, or acquire the securities or assets of
any other Person outside the Ordinary Course of Business;

          (6) Grant, extend or expand any employment terms for any of its directors, officers, and
employees outside the Ordinary Course of Business;

          (7) Commit to any of the foregoing; or

          (8) Issue any press release or public statement regarding the Company or any Products.

The foregoing notwithstanding, Company may take the following actions prior to Closing: (a)
increase its authorized shares of common stock to 125,000,000 Company Shares; provided, however,
that such Company Shares shall be subject to the restrictions set forth in Sections 3.E(2)
and (3) above; (b) perform its obligations and effectuate the transactions provided for in
the May 31, 2006 Purchase and Sale Agreement and Joint Escrow Instructions with Kidney Dialysis
Center of West Los Angeles, LLC, (c) sell all assets of the acute dialysis care division, with the
exception of its accounts receivable, for an amount sufficient to satisfy all of its outstanding
liabilities, and (d) make distributions to the former stockholders of Company pursuant to the AADP
Agreement. The provisions of this Section 3.E shall terminate in the event of the Closing
of the Technology Transaction or the termination of this Agreement.

     F. Expense Reimbursement. No later than the earlier of (i) thirty (30) days
after the date on which Shell has obtained total debt or equity investment of at least three
million five hundred thousand dollars ($3,500,000.00) or (ii) ninety (90) days after the date
hereof, Licensee shall reimburse Company’s reasonable and necessary expenses incurred in the
ordinary course of business consistent with past practices (“Company Expenses”), during the
period from the date hereof to the Closing (as defined therein) or termination of this Agreement.
All Company Expenses shall: (a) be only for the specific persons, services and expenses listed in
reasonable detail on the Budget contained in the Company Disclosure Schedule to the Merger
Agreement, (b) be payable hereunder only to the extent not paid pursuant to the Merger Agreement,
(c) be mutually agreed upon in advance of being reimbursed with regard to all Professional Fees set
forth in the Budget, and (d) include, but not be limited to, expenses already paid or accrued

10

 

relating to human clinical trials carried out or to be carried out on behalf of Licensor in Italy
and the United Kingdom as set forth in the Budget.

     G. Reasonable Access. Company and Shell will (and will cause each of their
Subsidiaries to) permit representatives of Shell and Company(including legal counsel and
accountants) to have reasonable access, during normal business hours and on reasonable notice, to
all information (including tax information) concerning the business, properties and personnel, of
or pertaining to Company and each of its Subsidiaries. Shell will treat and hold as such any
Confidential Information it receives from Company or any of its Subsidiaries in the course of the
reviews contemplated by this Section 3.G, will not use any of the Confidential Information
except in connection with this Agreement or the License Agreement, and, if this Agreement is
terminated for any reason whatsoever, agrees to return to Company all tangible embodiments (and all
copies) thereof that are in its possession.

     H. Notice of Developments. Each Party will give prompt written notice to the
others of any material adverse development causing a breach of any of its own representations and
warranties in this Agreement. No disclosure by any Party pursuant to this Section 3.H,
however, will be deemed to amend or supplement the Company Disclosure Schedule or the Shell
Disclosure Schedule or to prevent or cure any misrepresentation, breach of warranty, or breach of
covenant.

     I. Exclusivity. Company will not, and will not cause or permit any of its
Subsidiaries, directors or officers to: (1) solicit, initiate, encourage or entertain the
submission of any proposal or offer from any Person relating to the acquisition of all or
substantially all of the capital stock or assets of Company or any of its Subsidiaries (including
any acquisition structured as a merger, consolidation, or share exchange); (2) participate in any
discussions or negotiations regarding, furnish any information with respect to, assist or
participate in, or facilitate in any other manner any effort or attempt by any Person to do or seek
any of the foregoing, except in the case of directors to the extent their fiduciary duties may
require. Company will notify Shell immediately if any Person makes any proposal, offer, inquiry, or
contact with respect to any of the foregoing (an “Acquisition Proposal”) or if the Board of
Directors of Company shall have approved, recommended executed or entered into an Acquisition
Proposal, or resolved to do so. The foregoing notwithstanding, Company may solicit offers,
participate in negotiations, and execute any necessary agreements related solely to the sale of the
assets of LACD. The provisions of this Section 3.I shall terminate in the event of the
Closing of the Technology Transaction or the termination of this Agreement.

     J. Directors’ and Officers’ Indemnification and Insurance.

     (1) From and after the Effective Time, Shell will, or will cause the Surviving
Corporation to, (i) fulfill and honor in all respects the obligations to indemnify and hold
harmless the Shell’s, the Surviving Corporation’s, Company’s and each of their Subsidiaries’
present and former directors, officers and employees and their heirs, executors and assigns (each
an “Indemnified Party,” and collectively, the “Indemnified Personnel”), to the same
extent that such individuals are entitled to indemnification as of the date of this Agreement
pursuant to applicable law, articles of incorporation, bylaws and indemnification or other
agreements, if any,

11

 

in existence on the date hereof with, or for the benefit of, any such Indemnified Party arising out
of or pertaining to matters existing or occurring at or prior to the Effective Time and for acts or
omissions existing or occurring at or prior to the Effective Time (including for acts or omissions
occurring in connection with the approval of this Agreement and the consummation of the
transactions contemplated hereby), whether or not asserted or claimed prior thereto, and (ii)
include and caused to be maintained in effect in the Surviving Corporation’s (or any successor’s)
certificate of incorporation and bylaws for a period of five years after the Effective Time,
subject to any limitation imposed from time to time under applicable law, provisions regarding
elimination of liability of directors, indemnification of officers, directors and employees, and
advancement of expenses, that are at least as favorable to the Indemnified Personnel as those set
forth in the current articles of incorporation and bylaws of the Company in effect on the date
hereof.

     (2) In the event that any claim, action, suit, proceeding or investigation involving any
Indemnified Party is brought or initiated within five years after the Effective Time and arises out
of or pertains to any actual or alleged action or omission in his or her capacity as an officer,
director or employee of Company or any of its Subsidiaries occurring prior to the Effective Time,
or arises out of or pertains to the transactions contemplated by this Agreement, in each case for
which such Indemnified Party is indemnified under this
Section 3.J, except as otherwise
required by applicable law or contract or policy terms, (i) the Indemnified Personnel, may, at
their option, (A) elect to retain individual counsel at their own expense or (B), as a group, elect
to retain only one law firm to represent such Indemnified Personnel, which counsel shall be counsel
of Shell in addition to local counsel (provided that if the use of counsel of Shell would be
expected under applicable standards of professional conduct to give rise to a conflict between the
position of the Indemnified Personnel and that of Shell, the Indemnified Personnel shall be
entitled instead to be represented, either as a group by one counsel, or individually by separate
counsel at their own expense, in addition to local counsel, selected by the Indemnified Personnel,
and reasonably satisfactory to Shell), (ii) after the Effective Time, Shell and the Surviving
Corporation will pay the reasonable fees and expenses of all such counsel, promptly after
statements therefor are received and (iii) Shell and the Surviving Corporation will cooperate in
the defense of any such matter; provided, however, that Shell and the Surviving Corporation will
not be liable for any settlement effected without their written consent (which consent will not be
unreasonably withheld, delayed, or conditioned); and provided, further, that, in the event that any
claim or claims for indemnification are asserted or made within such five-year period, all rights
to indemnification are asserted or made within such five-year period, all rights to indemnification
in respect of any such claim or claims will continue until the disposition of any and all such
claims. Any Indemnified Personnel wishing to claim indemnification under this Section 3.J,
upon learning of such claim, action, suit, proceeding or investigation, shall promptly notify Shell
and the Surviving Corporation (provided that the failure to so notify Shell or the Surviving
Corporation shall not relieve such entity from any liability that it may have under this
Section 3.J, except to the extent that such failure prejudices such entity), and shall
deliver to Shell and the Surviving Corporation the undertaking contemplated by Section 145(e) of
the DGCL.

     (3) At the Closing of the Merger, Shell will, or will cause the Surviving Corporation to,
secure a “tail” on the Company’s existing directors’ and officers’ insurance policies, which will
provide Company, each individual serving as a director or officer of Company as of the date of

12

 

this Agreement or of the Surviving Corporation at the Closing of the Merger, and such other
Persons, if any, currently covered by such existing directors’ and officers’ insurance policies
with coverage on terms and in amounts that are no less favorable than those of the Company’s
policies in effect on the date hereof, or obtain substantially similar coverage for such persons,
for a period of at least five (5) years from the Effective Time.

     (4) Notwithstanding anything in the Agreement to the contrary, the provisions of this
Section 3.J are intended to be for the benefit of, and will be enforceable by, the
Indemnified Personnel, their heirs and representatives, and may not be amended or repealed without
the prior written consent of the affected Indemnified Personnel, and are in addition to, and not in
substitution for, any other rights to indemnification or contribution that such Indemnified
Personnel may have by contract or applicable law.

     (5) Notwithstanding anything in this Agreement to the contrary, in the event that Shell
or the Surviving Corporation or any of their respective successors or assigns
(i) consolidates with or merges into any other person and is not the continuing or surviving
corporation or entity of such consolidation or merger, or (ii) transfers or conveys all or
substantially all its properties and assets to any person, then, and in each such case, Shell or
Surviving Corporation shall cause proper provisions to be made so that the successors and assigns
of Shell or the Surviving Corporation, as the case may be, assume the obligations set forth in this
Section 3.J.

     K. Indemnification of Company and Majority Stockholders. Shell shall at all
times indemnify and hold harmless Company and the Majority Stockholders and their respective
Affiliates, Subsidiaries, directors, officers, employees, representatives, attorneys and agents
from any and all costs, expenses, losses, damages and liabilities incurred or suffered, directly or
indirectly, by any of them (including, without limitation, legal fees and expenses) resulting from
or attributable to:

          (1) The breach of, or misstatement in, any one or more of the representations, warranties, or
covenants of either Shell or Merger Subsidiary made in or pursuant to this Agreement or any other
Merger Document;

          (2) Any claims, demands, suits, investigations, proceedings or actions by any third party
containing or relating to allegations that, if true, would constitute a breach of, or misstatement
in, any one or more of the representations, warranties, or covenants of either Shell or Merger
Subsidiary made in or pursuant to this Agreement or any other Merger Document; or

          (3) Any claims, demands, suits, investigations, proceedings or actions by Company stockholders
against Company arising from or connected with the transactions contemplated by this Agreement or
any other Merger Documents; provided, however, that Shell shall not have any obligation under this
Section 3.K(3) with respect to any claims, demands, suits, investigations, proceedings or
actions to the extent any resulting liability is strictly and solely attributable to Company’s
breach of any material representation, warranty or obligation hereunder or Company’s gross
negligence or willful misconduct.

13

 

     L. Defense of Claims. If any Party has received actual notice or any claim
asserted or any action or administrative or other proceeding commenced in respect of which claim,
action, or proceeding indemnity properly may be sought against another Party or Parties pursuant
Section 3.K above (such Party or Parties, individually and collectively, the
“Indemnitor”), the Party or Parties seeking indemnity (such Party or Parties, individually
and collectively, the “Indemnitee”) will give notice in writing to the Indemnitor.

          (1) Within ten (10) days after the earlier of (a) receipt of such notice or (b) receipt of
actual notice by Indemnitor from sources other than Indemnitee, Indemnitor may give Indemnitee
written notice of its election to conduct the defense of such claim, action, or proceeding at its
own expense. If Indemnitor has given Indemnitee such notice of election to conduct the defense,
Indemnitor may conduct the defense at its expense, but Indemnitee may nevertheless have the right
to participate in the defense at the expense of Indemnitor.

          (2) If Indemnitor has not notified Indemnitee in writing (within the time period above
provided) of its election to conduct the defense of such claim, action, or proceeding, Indemnitee
may (but need not) conduct the defense of such claim, action, or proceeding at the expense of
Indemnitor. Indemnitee may at any time notify Indemnitor of Indemnitee’s intention to settle,
compromise, or satisfy any such claim, action, or proceeding (the defense of which Indemnitor has
not previously elected to conduct) and may make such settlement, compromise, or satisfaction at the
expense of Indemnitor unless Indemnitor notifies Indemnitee in writing (within five (5) days after
receipt of such notice of intention to settle, compromise, or satisfy) of its election to assume,
at Indemnitor’s sole expense, the defense of any such claim, action, or proceeding and promptly
take appropriate action to implement such defense.

          (3) Any settlement, compromise, or satisfaction made by Indemnitee or any such final judgment
or decree entered in any claim, action, or proceeding defended only by Indemnitee pursuant to this
Section 3.L, regardless of amount or terms, will be deemed to have been consented to by,
and will be binding on, Indemnitor as fully as though Indemnitor had assumed the defense and a
final judgment or decree had been entered in such proceeding or action by a court of competent
jurisdiction in the amount of such settlement, compromise, satisfaction, judgment, or decree.

          (4) If Indemnitor has elected under this Section 3.L to conduct the defense of any
claim, action, or proceeding, then Indemnitor will be obligated to pay the amount of any adverse
final judgment or decree rendered with respect to such claim, action, or proceeding. If Indemnitor
elects to settle, compromise, or satisfy any claim, action, or proceeding defended by it, the cost
of any such settlement, compromise, or satisfaction will be borne entirely by Indemnitor and may be
made only with the prior written consent of Indemnitee, such consent not to be unreasonably
withheld.

          (5) All Parties will use all reasonable efforts to cooperate fully with respect to the defense
of any claim, action, or proceeding covered by this Section 3.L.

14

 

     (M) Issuance of Shell Shares. Shell will not issue any Shell Shares except
for such consideration, having a value not less than the par value thereof, as determined from time
to time by the board of directors, or by the stockholders if the certificate of incorporation so
provides, in accordance with Sections 152 and 153 of the DGCL.

4. Company’s Representations And Warranties.

     The Company represents and warrants to Shell that the statements contained in this
Section 4 are correct and complete as of the date of this Agreement and will be correct and
complete as of the Closing, as though made then and as though the Closing were substituted for the
date of this Agreement throughout this Section 4, except as set forth in the disclosure
schedule attached to this Agreement as Exhibit L (the “Company Disclosure
Schedule”) corresponding to the Section of this Agreement, to which any of the following
representations and warranties specifically relate, or as disclosed in another section of the
Company Disclosure Schedule, if it is reasonably apparent on the face of the disclosure that it is
applicable to another Section of this Agreement, or in the Company Public Reports:

     A. Organization, Qualification, and Corporate Power. Each of Company and its
Subsidiaries is a corporation duly organized, validly existing, and in good standing under the laws
of the jurisdiction of its incorporation. Each of Company and its Subsidiaries is duly authorized
to conduct business and is in good standing under the laws of each jurisdiction where such
qualification is required. Company and its Subsidiaries has full corporate power and authority to
carry on the business in which it is engaged and to own and use the properties owned and used by
it.

     B. Capitalization. The entire authorized capital stock of Company consists solely of
125,000,000 Company Shares, of which 48,333,738 Company Shares are issued and
outstanding, and 5,000,000shares of preferred stock, none of which are issued or
outstanding. All of the issued and outstanding Company Shares have been duly authorized and are
validly issued, fully paid, non-assessable and free of preemptive rights, and were issued in
compliance with all applicable state and federal securities laws. Exhibits F and G set
forth a full and complete listing of all Company Securities. Except as set forth in such
Exhibits F and G, there are no: (1) other outstanding or authorized shares, options,
warrants, purchase rights, subscription rights, conversion rights, exchange rights, or other
contracts or commitments of any kind that could require Company to issue, sell, or otherwise cause
to become outstanding any of its capital stock.; (2) equity securities, debt securities or
instruments convertible into or exchangeable for shares of such stock; or (3) outstanding or
authorized stock appreciation, phantom stock, profit participation, or similar rights with respect
to Company.

     C. Authorization of Transaction. Company has all requisite power and authority,
including full corporate power and authority, to execute and deliver this Agreement and to perform
its obligations hereunder and to consummate the transactions contemplated hereby. The execution and
delivery of this Agreement by Company and the consummation by Company of the transactions
contemplated hereby have been duly and validly authorized by all necessary corporate action by
Company and, except as set forth herein, no other corporate proceedings on the part of Company and
no shareholder vote or consent are necessary to authorize this

15

 

Agreement or to consummate the transactions contemplated hereby. This Agreement has been
duly and validly executed and delivered by Company and each Majority Stockholder. This Agreement
and all other agreements and obligations entered into and undertaken in connection with the
transactions contemplated hereby to which Company and each Majority Stockholder is a party
constitute the valid and legally binding obligations of Company and each such Majority Stockholder,
enforceable against Company and each such Majority Stockholder in accordance with their respective
terms.

     D. Non-Contravention. Neither the execution and delivery of this Agreement, nor the
consummation of the transactions contemplated hereby, will (i) violate any constitution, statute,
regulation, rule, injunction, judgment, order, decree, ruling, charge, or other restriction of any
government, governmental agency, or court to which Company or any of its Subsidiaries is subject or
any provision of the charter or bylaws of Company or any of its Subsidiaries, or (ii) conflict
with, result in a breach of, constitute a default under, result in the acceleration of, create in
any party the right to accelerate, terminate, modify, or cancel, or require any notice under any
agreement, contract, lease, license, instrument, or other arrangement to which Company or any of
its Subsidiaries is a party or by which it is bound or to which any of its assets is subject (or
result in the imposition of any Lien upon any of its assets). Other than in connection with the
provisions of the DGCL, the CGLC to the extent applicable, the Exchange Act, the Securities Act,
and state securities laws, neither Company nor any of its Subsidiaries needs to give any notice to,
make any filing with, or obtain any authorization, consent, or approval of any government or
governmental agency in order for the Parties to consummate the transactions contemplated by this
Agreement.

     E. Filings with SEC. Except as set forth on the Company Disclosure Schedule, Company
has timely made all filings with the SEC that it has been required to make under the Securities Act
and the Exchange Act (collectively the “Company Public Reports”) since December 31, 2001,
and, to the Knowledge of the current officers and directors of Company, since Company Public
Reports were first required to be filed. Each of the Company Public Reports has complied with the
Securities Act and the Exchange Act in all material respects. None of the Company Public Reports,
as of their respective dates, contained any untrue statement of a material fact or omitted to state
a material fact necessary in order to make the statements made therein, in light of the
circumstances under which they were made, not misleading.

     F. Financial Statements. Company has filed quarterly reports on Form 10-Q for the
fiscal quarter ended March 31, 2006 and an annual report on Form 10-K for the fiscal year ended
December 31, 2005 (“Year End”). The financial statements included in or incorporated by
reference into these Company Public Reports (including the related notes and schedules) have been
prepared in accordance with GAAP throughout the periods covered thereby, present fairly the
financial condition of Company and its Subsidiaries as of the indicated dates and the results of
operations of Company and its Subsidiaries for the indicated periods and are correct and complete
in all respects, and are consistent with the books and records of Company and its Subsidiaries;
provided, however, that the interim statements are subject to normal year-end adjustments.

16

 

     G. Events Subsequent to Year End. Since Year End, there has not been any
Adverse Change.

     H. Undisclosed Liabilities. Neither Company nor any of its Subsidiaries has any
liability of any kind, whether known or unknown, whether asserted or unasserted, whether absolute
or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, and whether due or
to become due, including any liability for taxes, except for (i) liabilities set forth on the face
of the balance sheet dated as of Year End (rather than in any notes thereto) and (ii) liabilities
that have arisen after Year End in the Ordinary Course of Business (none of which results from,
arises out of, relates to, is in the nature of, or was caused by any breach of contract, breach of
warranty, tort, infringement, or violation of law). As of the Closing, neither Company nor any of
its Subsidiaries will have any liability of any kind, whether known or unknown, whether asserted or
unasserted, whether absolute or contingent, whether accrued or unaccrued, whether liquidated or
unliquidated, and whether due or to become due.

     I. Brokers’ Fees. Except as set forth on the Company Disclosure Schedule,
neither Company nor any of its Subsidiaries has any liability or obligation to pay any fees or
commissions to any broker, finder, or agent with respect to the
transactions contemplated by this
Agreement.

     J. Tax Treatment. Company operates at least one significant historic business
line, or owns at least a significant portion of its historic business assets, in each case within
the meaning of Treas. Reg. §1.368-l(d). Neither Company nor, to the Knowledge of Company, any of
its Affiliates has taken or agreed to take action that would prevent the Merger from constituting a
reorganization qualifying under the provisions of Section 354 of the Code.

     K. Disclosures. The Company Statement will comply with the Exchange Act in all
material respects. The Company Statement will not contain any untrue statement of a material fact
or omit to state a material fact necessary in order to make the statements made therein, in light
of the circumstances under which they will be made, not misleading; provided, however, that Company
makes no representation or warranty with respect to any information that Shell will supply
specifically for use in the Company Statement. None of the information that Company will supply
specifically for use in the Shell Statement or the Registration Statement will contain any untrue
statement of a material fact or omit to state a material fact necessary in order to make the
statements made therein, in light of the circumstances under which they will be made, not
misleading.

     L. Litigation. There is no action, suit, legal or administrative proceeding or
investigation pending, or to Company’s Knowledge threatened, against or involving Company (either
as a plaintiff or defendant) before any court or governmental agency, authority, body or
arbitrator. Neither Company nor to its Knowledge any officer, director or employee of Company, has
been permanently or temporarily enjoined by any order, judgment or decree of any court or any
governmental agency, authority or body from engaging in or continuing any conduct or practice in
connection with the business, assets, or properties of Company. There in existence on the date
hereof any order, judgment or decree of any court, tribunal or agency enjoining or

17

 

requiring Company to take any action of any kind with respect to its business, assets or
properties.

     M. Insurance. To the Knowledge of the current officers and directors of Company,
no material claims were made under any policies of insurance from the formation of the Company. To
the Knowledge of Company, no material claims were made under any policies of insurance from
December 31, 1996 to December 31, 2001. Except as set forth on the Company Disclosure Schedule, no
material claims have been made under any policies of insurance since December 31, 2001. True,
correct, and complete copies of all Company insurance policies have been made available to Shell.
All current insurance policies are in full force and effect, are in amounts of a nature that are
adequate and customary for Company’s business, and to the Knowledge of Company are sufficient for
compliance with all legal requirements and agreements to which it is a party or by which it is
bound. All premiums due on current policies or renewals have been paid, and there is no material
default under any of the policies.

     N. Tax Matters.

          (1) Within the times and in the manner prescribed by law, Company has filed all federal, state
and local tax returns and all tax returns for other governing bodies having jurisdiction to levy
taxes upon it which are required to be filed;

          (2) Company
has paid all taxes, interest, penalties, assessments and deficiencies which have become due, including without limitation income, franchise, real estate,
and sales and withholding taxes;

          (3) All tax returns filed, or to be filed by Company before the Closing, for all taxable years
since December 31, 2001 constitute complete and accurate representations of the respective tax
liabilities of Company for such years, to the Knowledge of Company all tax returns filed by Company
for all taxable years from January 31, 1997 to December 31, 2001 constitute complete and accurate
representations of the respective tax liabilities of Company for such years, and to the Knowledge
of the current officers and directors of Company all tax returns filed by Company for all taxable
years from formation of the Company constitute complete and accurate representations of the
respective tax liabilities of Company for such years.

          (4) Company has not waived or extended any applicable statute of limitations relating to the
assessment of federal, state or local taxes;

          (5) No examinations of the federal, state or local tax returns of Company are currently in
progress nor threatened and no deficiencies have been asserted or to its Knowledge assessed against
Company as a result of any audit by the Internal Revenue Service or any state or local taxing
authority and no such deficiency has been proposed or threatened;

          (6) There are no pending or threatened audits, assessments or other actions relating to any
liability in respect of taxes of Company by any tax authority nor are there any matters under
discussion with any tax authority with respect to taxes of Company;

18

 

          (7) Company has not filed a consent pursuant to Section 341(f) of the Code relating to
collapsible corporations nor has Company agreed to have Section 341(f)(2) of the Code apply to any
disposition of a subsection (f) asset as such term is defined in
Section 341(f)(4) of the Code; and

          (8) Company has filed all required state and federal income tax returns for all periods
through December 31, 2003, and will file all such returns for
all periods through December 31, 2005
prior to Closing. Company does not and will not owe any taxes or penalties for any such periods.

     O. Books and Records. The general ledger and books of account of Company, all
minute books of Company, all federal, state and local income, franchise, property and other tax
returns filed by Company, all reports and filings with the SEC by Company, all of which have been
made available to Shell, are in all material respects complete and correct and have been maintained
in accordance with good business practice and in accordance with all applicable procedures required
by laws and regulations.

     P. Contracts and Commitments. True, complete, and correct copies or lists of
the following contracts and agreements, whether written or oral, have been made available to Shell:

          (1) All loan agreements, indentures, mortgages, guaranties to which Company is a party or by
which Company or any of its property is bound and any other agreement evidencing indebtedness in
excess of $10,000;

          (2) All pledges, conditional sale or title retention agreements, security agreements,
equipment obligations, personal property leases and lease purchase agreements to which Company is a
party or by which Company or any of its property is bound, evidencing indebtedness in excess of
$10,000;

          (3) All contracts, agreements, commitments, purchase orders or other understandings or
arrangements to which Company is a party or by which Company or any of its property is bound that
involve payments or receipts by Company of more than $10,000 in the case of any single contract,
agreement, commitment, understanding or arrangement under which full performance (including
payment) has not been rendered by all parties thereto;

          (4) All collective bargaining agreements, employment and consulting
agreements providing for payments in excess of $10,000 per year, executive compensation plans,
bonus plans, deferred compensation agreements, pension plans, retirement plans, employee stock
option or stock purchase plans and group life, health and accident insurance and other employee
benefit plans, agreements, arrangements or commitments to which Company is a party or by which
Company or any of its property is bound;

          (5) All agency, distributor, sales representative, franchise or similar agreements
providing for payments in excess of $10,000 to which Company is a party or by which Company or
any of its property is bound;

19

 

          (6) All agreements, understandings or arrangements in excess of $10,000 individually between
or among Company and any director, officer, stockholder or, to Company’s Knowledge, affiliate or
family member of such Person; and

          (7) All contracts, agreements or other arrangements imposing a non competition
obligation on Company.

          (8) Every contract or agreement of any kind to which Company is a party will not bind or
obligate Company in any manner as of the Closing Date.

     Q. Compliance with Agreements and Laws.

          (1) To its Knowledge, (a) Company has all requisite licenses, permits and certificates,
including environmental, health and safety permits, from federal, state and local authorities
necessary to conduct its business and own and operate its assets including, without limitation all
necessary approvals, licenses, and permits from the FDA, except where the failure to have such
permits would not reasonably be expected to have an Adverse Effect, true, correct, and complete
copies or list of which has been made available to Shell; (b) Company is not in violation of any
law, regulation or ordinance (including, without limitation, laws, regulations or ordinances
relating to building, zoning, environmental, disposal of hazardous waste, land use or similar
matters) relating to its properties, the enforcement of which would have an Adverse Effect; and (c)
the business of Company as conducted since December 31, 1996 has not violated, and as of the
Closing does not violate, in any material respect, any federal, state, local or foreign laws,
regulations or orders (including, but not limited to, any of the foregoing relating to FDA research
and development regulations and approval processes, employment discrimination, occupational safety,
environmental protection, hazardous waste, conservation, or corrupt practices), the enforcement of
which would have an Adverse Effect. To the Knowledge of the current officers and directors of
Company, the business of Company from formation did not violate, in any material respect, any
federal, state, local or foreign laws, regulations or orders (including, but not limited to, any of
the foregoing relating to FDA research and development regulations and approval processes,
employment discrimination, occupational safety, environmental protection, hazardous waste,
conservation, or corrupt practices), the enforcement of which would have an Adverse Effect. Company
has not had notice or communication from any federal, state or local governmental or regulatory
authority or otherwise of any such violation or noncompliance.

          (2) To its Knowledge, Company is not in violation of any federal, state, county or municipal
authority law, ruling, order, decree, regulation, permit, or other environmental or hazardous waste
requirement applicable to Company relating to health, safety, pollution, hazardous waste,
environmental or other similar matters, which has not been entirely corrected and which has or
would reasonably be expected to have an Adverse Effect.

     R. Employee Relations.

          (1) To its Knowledge, Company is in material compliance with all federal, state, and
municipal laws respecting employment and employment practices, terms and

20

 

conditions of employment, and wages and hours, and is not engaged in any unfair labor practice, and
there are no arrears in the payment of wages or social security taxes.

          (2) None of the employees of Company is represented by any labor union;

          (3) There is no unfair labor practice complaint against Company pending before the
National Labor Relations Board or any state or local agency;

          (4) There is no pending labor strike or other material labor trouble affecting Company
(including, without limitation, any known organizational drive); and

          (5) There is no material labor grievance pending against Company.

     S. Employee Benefit Plans.

          (1) Company has no (a) employee benefit plans as defined in ERISA Section 3(3), (b)
bonus, stock option, stock purchase, incentive, deferred compensation, supplemental
retirement, severance or other similar employee benefit plans, or (c) material unexpired
severance agreements with any current or former employee of Company.

          (2) With respect to such plans, individually and in the aggregate, no event has occurred and,
to its Knowledge, there exists no condition or set of circumstances in connection with which
Company could be subject to any liability that is reasonably likely to have an Adverse Effect under
ERISA, the Code or any other applicable law.

          (3) With respect to such plans, individually and in the aggregate, there are no funded benefit
obligations for which contributions have not been made or properly accrued and there are no
unfunded benefit obligations that have not been accounted for by reserves, which obligations are
reasonably likely to have an Adverse Effect.

          (4) Except as set forth on the Company Disclosure Schedule, Company is not a party to any (a)
agreement with any officer or other key employee of Company, (b) agreement with any officer of
Company providing any term of employment or compensation guarantee extending for a period longer
than the Closing, or (c) agreement or plan, including any stock option plan, stock appreciation
right plan, restricted stock plan or stock purchase plan, which will remain in effect or have any
benefits as of the Closing.

     T. Indebtedness to and from Affiliates. Except as set forth on the Company
Disclosure Schedule, Company is not indebted, directly or to its Knowledge indirectly, to any
officer, director or greater than 10% stockholder of Company in any amount other than for salaries
for services rendered or reimbursable business expenses, and no such Person is indebted to Company
except for advances made to employees of Company in the ordinary course of business to meet
reimbursable business expenses.

     U. Banking Facilities. Its disclosure schedule sets forth a true, correct, and
complete list of:

21

 

          (1) Each bank, savings and loan or similar financial institution in which Company has an
account or safety deposit box and the numbers of the accounts or safety deposit boxes maintained by
Company thereat; and

          (2) The names of all signatories authorized to draw on each such account or to have access to
any such safety deposit box facility.

     V. Powers of Attorney and Suretyships. Company does not have (i) any general
powers of attorney outstanding, whether as grantor or grantee thereof, or (ii) except as reflected
in its financial statements, any obligation or liability, whether actual, accrued, accruing,
contingent or otherwise, as guarantor, surety, co-signer, endorser, co-maker, indemnitor, or
otherwise in respect of the obligation of any person, corporation, partnership, joint venture,
association, organization or other entity, except as endorser or maker of checks or letters of
credit, respectively, endorsed or made in the ordinary course of business.

     W. Conflicts of Interest. Except as set forth in Section 4.T hereof or
on the Company Disclosure Schedule, no officer, director, or greater than ten percent (10%)
stockholder of Company nor, to its Knowledge, any affiliate of any such Person, now has or within
the last three (3) years had, either directly or indirectly:

          (1) An equity or debt interest in any Person that furnishes or sells or during such period
furnished or sold services or products to Shell, or purchases or during such period purchased from
Company any goods or services, or otherwise during such period did business with Company; or

          (2) A beneficial interest in any contract, commitment or agreement to which Company is or was
a party or under which Company is or was obligated or bound or to which its properties may be or
may have been subject, other than stock options and other contracts, commitments or agreements
between Company and such persons in their capacities as employees, officers, directors or
stockholders of Company.

     X. Stockholder Claims. There are no existing claims against Company by any
current or former stockholder of Company, and to the Knowledge of Company, no facts or
circumstances reasonably likely to result in any such claim.

     Y. Affiliates. Except as set forth on the Company Disclosure Schedule,, there
are no persons other than the Parties who, to the Knowledge of Company, may be deemed to be
Affiliates of Company.

     Z. Intellectual Property.

          (1) No claim has been asserted to Company that the conduct of the business of
Company as currently conducted infringes upon or may infringe upon or misappropriates the
Intellectual Property rights of any third party, and to the Knowledge of Company, the conduct of
the business of Company as currently conducted does not infringe upon or misappropriate the
Intellectual Property rights of any third party;

22

 

          (2) Except as set forth on the Company Disclosure Schedule, with respect to each item of
Intellectual Property owned by Company and material to the business, financial condition or results
of operations of Company (the “Company Owned Intellectual Property”), Company is
the sole and exclusive owner of the entire right, title and interest in and to such Company Owned
Intellectual Property and is entitled to use such Company Owned Intellectual Property in the
continued operation of its business;

          (3) With respect to each item of Intellectual Property licensed to Company that is material to
the business of Company as currently conducted (the “Company Licensed Intellectual
Property”), Company has the right to use such Company Licensed Intellectual Property in the
continued operation of its business in accordance with the terms of the license agreement governing
such Company Licensed Intellectual Property;

          (4) The Company Owned Intellectual Property has not been adjudged invalid or unenforceable, in
whole or in part, by any governmental agency, authority, or court of competent jurisdiction; to the
Knowledge of Company, the Company Owned Intellectual Property is valid and enforceable, and no
Person is engaging in any activity that infringes upon the Company Owned Intellectual Property; and

          (5) With the exception of the execution of the License Agreement, neither the execution of
this Agreement nor the consummation of any transaction pursuant hereto shall adversely affect any
of Company’s rights with respect to the Company Owned Intellectual Property or the Company Licensed
Intellectual Property.

5. Shell’s Representations And Warranties.

     Each of Shell and Merger Subsidiary represents and warrants to Company that the statements
contained in this Section 5 are correct and complete as of the date of this Agreement and
will be correct and complete as of the Closing (as though made then and as though the Closing were
substituted for the date of this Agreement throughout this Section 5, except as set forth
in the except as set forth in the disclosure schedule attached this Agreement as Exhibit M
(the “Shell Disclosure Schedule”) corresponding to the Section of this Agreement, to
which any of the following representations and warranties specifically relate, or as disclosed in
another section of the Shell Disclosure Schedule, if it is reasonably apparent on the face of the
disclosure that it is applicable to another Section of this Agreement:

     A. Organization. Each of Shell and Merger Subsidiary is a corporation (or other
entity) duly organized, validly existing, and in good standing under the laws of the jurisdiction
of its incorporation (or other formation). Merger Subsidiary has had no business operations since
inception, and has no assets or liabilities of any kind, whether known or unknown, whether asserted
or unasserted, whether absolute or contingent, whether accrued or unaccrued, whether liquidated or
unliquidated, and whether due or to become due.

     B. Capitalization.

23

 

          (1) The authorized capital stock of Shell, and the Shell Shares issued and outstanding
as of the date of this Agreement, are as set forth in the Shell Public Reports. To Shell’s
Knowledge, there are no: (a) other outstanding or authorized shares, options, warrants, purchase
rights, subscription rights, conversion rights, exchange rights, or other contracts or commitments
of any kind that could require Shell to issue, sell, or otherwise cause to become outstanding any
of its capital stock; (b) equity securities, debt securities or instruments convertible into or
exchangeable for shares of such stock; or (c) outstanding or authorized stock appreciation, phantom
stock, profit participation, or similar rights with respect to Shell.

          (2) The entire authorized capital stock of Merger Subsidiary consists of one thousand (1,000)
shares of common stock, none of which are issued or outstanding. There are no: (a) other
outstanding or authorized shares, options, warrants, purchase rights, subscription rights,
conversion rights, exchange rights, or other contracts or commitments of any kind that could
require Merger Subsidiary to issue, sell, or otherwise cause to become outstanding any of its
capital stock; (b) equity securities, debt securities or instruments convertible into or
exchangeable for shares of such stock; or (c) outstanding or authorized stock appreciation,
phantom stock, profit participation, or similar rights with respect to Merger Subsidiary.

     C. Authorization of Transaction. Each of Shell and Merger Subsidiary has all requisite
power and authority, including full corporate power and authority, to execute and deliver this
Agreement and to perform its obligations hereunder and to consummate the transactions contemplated
hereby. The execution and delivery of this Agreement by Shell and Merger Sub and the consummation
by Shell and Merger Subsidiary of the transactions contemplated hereby have been duly and validly
authorized by all necessary corporate action by Shell and Merger Subsidiary and, except as set
forth herein, no other corporate proceedings on the part of Shell or Merger Subsidiary and no
shareholder vote or consent are necessary to authorize this Agreement or to consummate the
transactions contemplated hereby. This Agreement has been duly and validly executed and delivered
by Shell and Merger Subsidiary. This Agreement and all other agreements and obligations entered
into and undertaken in connection with the transactions contemplated hereby to which each of Shell,
Merger Subsidiary and CNL is a party constitute the valid and legally binding obligations of each
of Shell, Merger Subsidiary and CNL, enforceable against Shell, Merger Subsidiary and CNL in
accordance with their respective terms.

     D. Non-Contravention. Neither the execution and delivery of this Agreement, nor the
consummation of the transactions contemplated hereby, will (a) violate any constitution, statute,
regulation, rule, injunction, judgment, order, decree, ruling, charge, or other restriction of any
government, governmental agency, or court to which either Shell or Merger Subsidiary is subject or
any provision of the charter, bylaws, or other governing documents of either Shell or Merger
Subsidiary or (b) conflict with, result in a breach of, constitute a default under, result in the
acceleration of, create in any party the right to accelerate, terminate, modify, or cancel, or
require any notice under any agreement, contract, lease, license, instrument, or other arrangement
to which either Shell or Merger Subsidiary is a party or by which it is bound or to which any of
its assets is subject except where the violation, conflict, breach, default, acceleration,
termination, modification, cancellation, or failure to give notice would not have a Adverse Effect
on the ability of the Parties to consummate the transactions contemplated by this Agreement. Other

24

 

than in connection with the provisions of the DGCL, the Exchange Act, the Securities Act, and
applicable state securities laws, neither Shell nor Merger Subsidiary needs to give any notice to,
make any filing with, or obtain any authorization, consent, or approval of any government or
governmental agency in order for the Parties to consummate the transactions contemplated by this
Agreement except where the failure to give notice, to file, or to obtain any authorization,
consent, or approval would not have a Adverse Effect on the ability of the Parties to consummate
the transactions contemplated by this Agreement.

     E. Filings with SEC. Except as set forth on the Shell Disclosure Schedule, to the
Knowledge of the current officers and directors of Shell: Shell has timely made all filings with
the SEC that it has been required to make under the Securities Act and the Exchange Act
(collectively the “Shell Public Reports”) since Shell Public Reports were first required to
be filed; each of the Shell Public Reports has complied with the Securities Act and the Exchange
Act in all material respects; none of the Shell Public Reports, as of their respective dates,
contained any untrue statement of a material fact or omitted to state a material fact necessary in
order to make the statements made therein, in light of the circumstances under which they were
made, not misleading.

     F. Financial Statements. Shell has filed a quarterly report on Form 10-Q for the
fiscal quarter ended March 31 or June 30, 2006, and an annual report on Form 10-K for the fiscal
year ended December 31, 2005 (“Year End”). Except as set forth on the Shell Disclosure
Schedule, to the Knowledge of the current officers and directors of Shell, the financial statements
included in or incorporated by reference into the Shell Public Reports (including the related notes
and schedules) have been prepared in accordance with GAAP throughout the periods covered thereby,
present fairly the financial condition of Company and its Subsidiaries as of the indicated dates
and the results of operations of Shell and its Subsidiaries for the indicated periods and are
correct and complete in all respects, and are consistent with the books and records of Shell and
its Subsidiaries; provided, however, that the interim statements are subject to normal year-end
adjustments.

     G. Events Subsequent to Year End. Except as set forth on the Shell Disclosure
Schedule, to the Knowledge of the current officers and directors of Shell, there has not been any
Adverse Change since Year End.

     H. OTCBB Eligibility. To the Knowledge of the current officers and directors of
Shell, Shell meets all issuer and equity security requirements to permit an NASD member to quote
the Shell Shares on, the OTC Bulletin Board, other than the requirements of the Securities Act and
applicable state securities laws.

     I. Form S-3 Eligibility. To the Knowledge of the current officers and
directors of Shell, Shell meets all Registrant Requirements in order to use Form S-3 for the
registration of securities under the Act, including without limitation all requirements set forth
in Section I.A of the General Instructions to Form S-3 promulgated by the SEC.

     J. Undisclosed Liabilities. Except as set forth on the Shell Disclosure
Schedule, to the Knowledge of the current officers and directors of Shell, neither Shell nor Merger
Subsidiary

25

 

has any liability of any kind, whether known or unknown, whether asserted or unasserted, whether
absolute or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, and
whether due or to become due, including any liability for taxes, except for (1) liabilities set
forth on the face of the balance sheet dated as of Year End (rather than in any notes thereto) and
(2) liabilities that have arisen after Year End in the Ordinary Course of Business (none of which
results from, arises out of, relates to, is in the nature of, or was caused by any breach of
contract, breach of warranty, tort, infringement, or violation of law).

     K. Brokers’ Fees. Neither Shell nor Merger Subsidiary has any liability or
obligation to pay any fees or commissions to any broker, finder, or agent with respect to the
transactions contemplated by this Agreement for which Company or any of its Subsidiaries could
become liable or obligated.

     L. Tax Treatment. It is the present intention of Shell to continue at least one
significant historic business line of Company, or to use at least a significant portion of
Company’s historic business assets in a business, in each case within the meaning of Treas. Reg. §
1.368-1(d). Neither Shell or Merger Subsidiary nor, to the Knowledge of Shell, any of their
Affiliates has taken or agreed to take action that would prevent the Merger from constituting a
reorganization qualifying under the provisions of Section 354 of the Code.

     M. Disclosure. The Shell Statement and the Registration Statement will comply
with the Securities Act in all material respects. The Shell Statement and the Registration
Statement will not contain any untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements made therein, in light of the circumstances under which
they will be made, not misleading; provided, however, that Shell makes no representation or
warranty with respect to any information that Company will supply specifically for use in the Shell
Statement or the Registration Statement. None of the information that Shell and Merger Subsidiary
will supply specifically for use in the Company Statement will contain any untrue statement of a
material fact or omit to state a material fact necessary in order to make the statements made
therein, in light of the circumstances under which they will be made, not misleading.

     N. Litigation. There is no action, suit, legal or administrative proceeding or
investigation pending, or to Shell’s Knowledge threatened, against or involving Shell (either as a
plaintiff or defendant) before any court or governmental agency, authority, body or arbitrator.
Neither Shell nor to its Knowledge any officer, director or employee of Shell, has been permanently
or temporarily enjoined by any order, judgment or decree of any court or any governmental agency,
authority or body from engaging in or continuing any conduct or practice in connection with the
business, assets, or properties of Shell, Merger Subsidiary, or Company. There in existence on the
date hereof any order, judgment or decree of any court, tribunal or agency enjoining or requiring
Shell to take any action of any kind with respect to its business, assets or properties.

     O. Books and Records. The general ledger and books of account of Shell, all
minute books of Shell, all federal, state and local income, franchise, property and other tax
returns filed by Shell, all reports and filings with the SEC by Shell, all of which have been made
available to Company, are in all material respects complete and correct and have been maintained in

26

 

accordance with good business practice and in accordance with all applicable procedures
required by laws and regulations.

     P. Stockholder Claims. There are no existing claims against Shell by any
current or former stockholder of Shell, and to Shell’s Knowledge, no facts or circumstances
reasonably likely to result in any such claims.

     Q. Affiliates. Except for the Parties, there are no persons who, to the
Knowledge of Shell, may be deemed to be Affiliates of Shell.

     R. Operations of Merger Subsidiary. Merger Subsidiary is a direct, wholly owned
subsidiary of Shell, was formed solely for the purpose of engaging in the transactions contemplated
by this Agreement, has engaged in no other business activities and has conducted its operations
only as contemplated by this Agreement.

6. Termination of Merger Transaction.

     A. Termination. Any of the Parties may terminate the Merger Transaction
with the prior authorization of its board of directors, before or after stockholder approval, only
as provided in this Section 6.A below:

          (1) Shell may terminate the Merger Transaction by giving written notice to Company within
ninety (90) days following the date of this Agreement if Shell is not reasonably satisfied with the
results of its due diligence regarding the Company.

          (2) Shell may terminate the Merger Transaction by giving written notice to Company at any time
prior to the Closing of the Merger in the event of an Uncured Breach by Company.

          (3) Company may terminate the Merger Transaction by giving written notice to Shell and Merger
Subsidiary at any time prior to the Closing of the Merger in the event of an Uncured Breach by
Shell or Merger Subsidiary.

          (4) Company may terminate the Merger Transaction if the Closing of the Merger shall not have
been consummated on or before December 1, 2006, and either Party may terminate the Merger
Transaction if the Closing of the Merger shall not have been consummated on or before close of
business on Friday, December 29, 2006; provided, however, that the right to
terminate the Merger Transaction under this Section 6.A(4) shall not be available to any
party whose Uncured Breach has been the cause of, or resulted in, the failure of the Closing of the
Merger to have been consummated on or before such date. For the avoidance of doubt, notwithstanding
any other provision of this Agreement, under no circumstances, other than as caused by its own
Uncured Breach, will Shell have any obligation to issue or deliver any Shell Shares after December
31, 2006, unless the Parties mutually agree to extend such date.

          (5) Either Party may terminate the Merger Transaction, if a Governmental Authority of
competent jurisdiction shall have issued an order or taken any other action, in each case

27

 

which has become final and non-appealable, and which permanently restrains, enjoins or otherwise
prohibits the Closing of the Merger.

     B. Effect of Termination. If the Merger Transaction is terminated pursuant
to Section 6.A:

          (1) Company shall absolutely, unconditionally, validly and irrevocably sell, transfer, grant
and assign to Shell all of the Technology, including, but not limited to, the sole and exclusive
right, in perpetuity and throughout the Territory, to use, improve, expand and otherwise exploit
the Technology, to make (and have made), use, and sell the Licensed Products, and otherwise to
practice the inventions and the art that is embodied or described in the Licensor Patents, the
Licensor Patent Applications, and any improvements thereto made in whole or in part by Licensor
(whether or not patented) in connection with the Technology (each such capitalized term as defined
in the License Agreement), (the “Technology Transaction”);

          (2) At the Closing of the Technology Transaction and in consideration of the transfer provided
for in Section 6.B(2)(a), Shell shall deliver to Company validly issued, fully paid and
non-assessable Shell Shares in one of the following amounts:

               (i) If notice of termination is given pursuant to Section 6(A)(2) or (4),Nine
Million Six Hundred Thousand (9,600,000) Shell Shares; or

               (ii) If notice of termination is given pursuant to Section 6(A)(1), (3) or
(5),
Twelve Million Four Hundred Eighty Thousand (12,480,000) Shell Shares;

Provided, however, that if the total number of Shell Shares outstanding as of the date of this
Agreement is other than Ten Million Four Hundred Thousand (10,400,000), the number of Shell Shares
provided for in this Section 6.B(2) will be proportionately adjusted in accordance with the
Conversion Ratio as set forth in Section 1.F(5)(a): and

Provided, further, that if it is later determined by an arbitrator or court of competent
jurisdiction that a notice of termination was improper, or that the Agreement was terminated on a
different basis or pursuant to a different provision, the number of Shell Shares to be issued
pursuant to this Section 6.B(2) will be retroactively adjusted to the correct umber
pursuant to one of the foregoing subsections, and any difference between the Shell Shares issued
and the Shell Shares determined to be correct will be issued or returned for cancellation by the
appropriate Party to the other within ninety (90) days of any such final determination; and

          (3) Except for the provisions of Sections 1, 7 and 8 of the License Agreement, which shall
remain in full force and effect and be deemed incorporated herein by reference, the License
Agreement shall thereafter be terminated and be of no further force or effect whatsoever.

7. Definitions.

     “Adverse Effect” or “Adverse Change” means any effect or change that
would be, or could reasonably be expected to be, materially adverse to the business, assets,
financial condition, operating results, operations, or business prospects of Company, or to the
ability of

28

 

Company to consummate timely the transactions contemplated by this Agreement, regardless of whether
or not such adverse effect or change can be or has been cured at any time or whether Shell has
knowledge of such effect or change on the date hereof, including any adverse change, event,
development, or effect arising from or relating to: (a) general business or economic conditions,
including such conditions related to the business of Company, (b) national or international
political or social conditions, including the engagement by the United States in hostilities,
whether or not pursuant to the declaration of a national emergency or war, or the occurrence of any
military or terrorist attack upon the United States, or any of its territories, possessions, or
diplomatic or consular offices or upon any military installation, equipment or personnel of the
United States, (c) financial, banking, or securities markets, including any general suspension of
trading in, or limitation on prices for, securities on any national exchange or trading market, (d)
changes in GAAP, (e) changes in laws, rules, regulations, orders, or other binding directives
issued by any governmental entity, and (f) the taking of any action contemplated by this Agreement
and the other agreements contemplated hereby.

     “Affiliate” has the meaning set forth in Rule 12b-2 of the regulations promulgated
under the Exchange Act.

     “CGCL” means the Corporations Code of the State of California, as
amended.

     “CNL” means Consolidated National, LLC, a California limited liability company.

     “Code” means the Internal Revenue Code of 1986, as amended, or any succeeding law.

     “Company Share” means any share of the common stock, $0.01 par value per share, of
Company.

     “Company Stockholder” means any Person who holds any Company Shares.

     “Confidential Information” means material non-public information concerning the
business and affairs of Company and its Subsidiaries, that is confidential or proprietary in
nature, relating to (a) Company’s proprietary technology, including any patent applications, trade
secrets, methods, data, processes, formulas, instrumentation, techniques, know-how, procedures,
enhancements or improvements, or (b) Company’s products or services, systems, finances, methods of
operation, strategy, business plans, prospective or existing contracts or other business
arrangements, that Company uses reasonable efforts to identify as Confidential Information when
provided. Confidential Information does not include information that is or becomes: (i) part of the
public domain through no act or omission of the receiving Party, (ii) developed independently by
the receiving Party, or (iii) lawfully provided to the receiving Party by a third party not subject
to an obligation of confidentiality or otherwise prohibited from transmitting the information.

     “DGCL” means the General Corporation Law of the State of Delaware, as amended.

     “Dissenting Share” means any Company Share held of record by any stockholder who has
exercised applicable appraisal rights under the DGCL.

     “Exchange Act” means the Securities Exchange Act of 1934, as amended.

29

 

     “FDA” means the Food and Drag Administration, or any successor agency.

     “GAAP” means United States generally accepted accounting principles as in effect from
time to time, consistently applied.

     “Governmental Authority” means any national, state, municipal, local or foreign
government, any instrumentality, subdivision, court, administrative agency or commission or
other authority thereof, or any quasi-governmental or private body exercising any regulatory,
taxing, importing or other governmental or quasi-governmental authority.

     “Intellectual Property” means (a) United States, non-United States and international
patents, patent applications and statutory invention registrations, (b) trademarks, service marks,
trade dress, logos, trade names, corporate names and other source identifiers, and registrations
and applications for registration thereof, (c) copyrightable works, copyrights, and registrations
and applications for registration thereof, and (d) confidential and proprietary information,
including trade secrets and know-how.

     “IRS” means the Internal Revenue Service.

     “Knowledge” means actual knowledge after reasonable investigation.

     “Lien” means any mortgage, pledge, lien, encumbrance, charge, or other security
interest, other than (a) liens for taxes not yet due and payable or for taxes that the taxpayer is
contesting in good faith through appropriate proceedings, (b) purchase money liens and liens
securing rental payments under capital lease arrangements, and (c) other liens arising in the
Ordinary Course of Business and not incurred in connection with the borrowing of money.

     “Majority Stockholders” means Victor Gura, M.D., Robert M. Snukal and Leonardo
Berezovsky, M.D., individually and as Trustee of all Trusts holding Company Shares of which he is a
Trustee.

     “Merger Documents” means this Agreement, the Affiliate Agreements, the Voting
Agreements, the Registration Statement, the Company Statement, the Shell Statement, the AADP
Agreement, all SEC filings, all filings made pursuant to applicable state securities laws, and any
other documents executed or filed in connection with the transactions contemplated herein (but
excluding the License Agreement).

     “Ordinary Course of Business” means the ordinary course of business consistent with
past custom and practice, including with respect to nature, quantity and frequency.

     “Person” means an individual, a partnership, a corporation, a limited liability
company, an association, a joint stock company, a trust, a joint venture, an unincorporated
organization, any other business entity, or a governmental entity (or any department, agency, or
political subdivision thereof).

     “SEC” means the Securities and Exchange Commission.

30

 

     “Securities Act” means the Securities Act of 1933, as amended.

     “Shell Securities” means any Shell Share and any security exercisable or convertible
into Shell Shares.

     “Shell Share” means any share of the common stock of Shell.

     “Shell Stockholder” means any Person who holds any Shell
Shares.

     “Stockholder Approval” means the effective affirmative vote of the holders of a
majority of the Company Shares or Shell Shares, as the case may be, in favor of this Agreement and
the Merger.

     “Subsidiary” means, with respect to any Person, any corporation, limited liability
company, partnership, association, or other business entity of which (a) if a corporation, a
majority of the total voting power of shares of stock entitled (without regard to the occurrence of
any contingency) to vote in the election of directors, managers, or trustees thereof is at the time
owned or controlled, directly or indirectly, by that Person or one or more of the other
Subsidiaries of that Person or a combination thereof or (b) if a limited liability company,
partnership, association, or other business entity (other than a corporation), a majority of the
partnership or other similar ownership interests thereof is at the time owned or controlled,
directly or indirectly, by that Person or one or more Subsidiaries of that Person or a combination
thereof and for this purpose, a Person or Persons owns a majority ownership interest in such a
business entity (other than a corporation) if such Person or Persons will be allocated a majority
of such business entity’s gains or losses or will be or control any managing director or general
partner of such business entity (other than a corporation). The term “Subsidiary” will
include all Subsidiaries of such Subsidiary.

     “Uncured Breach” means an unexcused breach of any material representation, warranty or
covenant contained in this Agreement, in any material respect, following written notice reasonably
specifying the breach and the demanded manner of cure, if and when the breach has continued without
cure for a period of thirty (30) days after the notice of breach.

8. General.

     A. Press Releases and Public Announcements. No Party will issue any press
release or make any public announcement relating to the subject matter of this Agreement without
the prior written approval of the other Parties; provided, however, that any Party may make any
public disclosure it believes in good faith based upon advise of counsel is required by applicable
law or any listing or trading agreement concerning its publicly traded securities (in which case
the disclosing Party will use its best efforts to advise the other Party prior to making the
disclosure).

     B. No Third-Party Beneficiaries. This Agreement will not confer any rights or remedies
upon any Person other than the Parties and their respective successors and permitted assigns.

31

 

     C. Succession and Assignment. This Agreement will be binding upon and inure to the
benefit of the Parties named herein and their respective successors and permitted assigns. No Party
may assign either this Agreement or any of its rights, interests, or obligations hereunder without
the prior written approval of the other Parties.

     D. Headings. The section headings contained in this Agreement are inserted for
convenience only and will not affect in any way the meaning or interpretation of this Agreement.

     E. Notices. All notices, requests, demands, claims, and other communications hereunder
will be in writing. Any notice, request, demand, claim, or other communication hereunder will be
deemed duly given (i) when delivered personally to the recipient, (ii) one (1) business day after
being sent to the recipient by reputable overnight courier service, (iii) one (1) business day
after being sent to the recipient by facsimile transmission or electronic mail, or (iv) four (4)
business days after being mailed to the recipient by certified or registered mail, return receipt
requested and postage prepaid, and addressed to the intended recipient as set forth below:

If to Shell or Merger Subsidiary:

Xcorporeal, Inc.

c/o Greenberg Traurig, LLP

2450 Colorado Avenue, Suite 400E

Attn: Terren S. Peizer

Fax: (310) 586-0286

With a copy to:

Greenberg
Traurig, LLP
 2450 Colorado
Avenue, Suite 400E

 Santa Monica,
California 90404

 Attn: John C.
Kirkland, Esq.

Fax: (310) 586-0286

If to Company:

National Quality Care, Inc.
 9033
Wilshire Boulevard, Suite 501

Beverly Hills, California 90211

Attention: Robert M. Snukal

Fax:
(310) 840-5681

With a copy to:

Jenkins & Gilchrist, LLP

12100 Wilshire Boulevard, 15th Floor

Los Angeles, California 90025

Attn: Jeffrey P. Berg, Esq.

Fax: (310) 820-8859

32

 

Any Party may change the address to which notices, requests, demands, claims, and other
communications hereunder are to be delivered by giving the other Parties notice in the manner
herein set forth.

     F. Governing Law. This Agreement will be governed by and construed in accordance with
the domestic laws of the State of Delaware without giving effect to any choice or conflict of law
provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the
application of the laws of any jurisdiction other than the State of Delaware.

     G. Arbitration. Any dispute, controversy or claim arising out of or relating to this
Agreement, shall be resolved by final and binding arbitration before a retired judge at JAMS or its
successor in Santa Monica, California. The expenses of arbitration, the reasonable fees and costs
of legal counsel, experts, and evidence shall be awarded to the prevailing party. Any interim or
final award of the arbitrator may be entered in any court of competent jurisdiction.

     H. Severability. Any term or provision of this Agreement that is invalid or
unenforceable in any situation in any jurisdiction will not affect the validity or enforceability
of the remaining terms and provisions hereof or the validity or enforceability of the offending
term or provision in any other situation or in any other jurisdiction.

     I. Attorneys and Expenses. All Parties have been represented by their own
separate counsel in connection with this Agreement and the transactions contemplated hereby:
Greenberg Traurig, LLP and its attorneys have solely represented the interests of CNL and Shell,
and Jenkens & Gilchrist and its attorneys have solely represented the interests of Company. Each of
the Parties will bear its own costs and expenses (including legal fees and expenses) incurred in
connection with this Agreement and the transactions contemplated hereby.

     J. Attorneys’ Fees. If attorneys’ fees or other costs are incurred to secure
performance of any obligations hereunder, or to establish damages for the breach thereof or to
obtain any other appropriate relief, whether by way of prosecution or defense, the prevailing party
will be entitled to recover reasonable attorney’s fees and costs incurred in connection therewith,
including on appeal therefrom.

     K. Construction. The Parties have participated jointly in the negotiation and
drafting of this Agreement. In the event an ambiguity or question of intent or interpretation
arises, this Agreement will be construed as if drafted jointly by the Parties and no presumption or
burden of proof will arise favoring or disfavoring any Party by virtue of the authorship of any of
the provisions of this Agreement. Any reference to any federal, state, local, or foreign statute or
law will be deemed also to refer to all rules and regulations promulgated thereunder, unless the
context otherwise requires. The word “including” will mean including without limitation. Time is of
the essence of each provision of this Agreement.

     L. Incorporation of Exhibits. The Exhibits identified in this Agreement
are incorporated herein by reference and made a part hereof.

33

 

     M. Amendments and Waivers. The Parties may mutually amend any provision of this
Agreement at any time prior to the Closing with the prior authorization of their respective boards
of directors; provided, however, that any amendment effected subsequent to stockholder approval
will be subject to the restrictions contained in the DGCL. No amendment of any provision of this
Agreement will be valid unless the same will be in writing and signed by all of the Parties. No
waiver by any Party of any provision of this Agreement or any default, misrepresentation, or breach
of warranty or covenant hereunder, whether intentional or not, will be valid unless the same will
be in writing and signed by the Party making such waiver nor will such waiver be deemed to extend
to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder
or affect in any way any rights arising by virtue of any prior or subsequent such default,
misrepresentation, or breach of warranty or covenant.

     N. Survival. All of the representations, warranties, and covenants of the
Parties contained in this Agreement shall survive the Closing, and continue in full force and
effect for a period of one (1) year thereafter.

     O. Termination of Agreement. Any of the Parties may jointly terminate
this Agreement with the prior authorization of its board of directors, before or after
stockholder approval, by mutual written consent at any time prior to the Closing.

     P. Counterparts. This Agreement may be executed in one or more counterparts,
including by means of facsimile, each of which will be deemed an original, and all of which
together will constitute one and the same instrument.

34

 

     Q. Entire Agreement. This Agreement, including the attached Exhibits and
documents referred to herein, constitutes the entire agreement among the Parties, and supersedes
all prior or contemporaneous understandings or agreements, whether written or oral. Neither party
has relied upon any promise, representation or undertaking not expressly set forth herein. To the
extent that there is any conflict between any provision in this Agreement and any provision in any
other agreement to which the Parties are also parties, the provision of this Agreement shall
govern.

     IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the date first above
written.

	 	 	 	 	 
	COMPANY:	 	 
	 
	 	 	 	 
	NATIONAL QUALITY CARE, INC.	 	 
	 
	 	 	 	 
	By:

	 	/s/ Robert M. Snukal	 	 
	 

	 	 

Robert M. Snukal, Chief Executive Officer
	 	 
	 
	 	 	 	 
	By:

	 	/s/ Victor Gura	 	 
	 

	 	 

Victor Gura, M.D., Chief Scientific Officer
	 	 
	 
	 	 	 	 
	SHELL:	 	 
	 
	 	 	 	 
	XCORPOREAL, INC.	 	 
	 
	 	 	 	 
	By:

	 	/s/ Terren S. Peizer	 	 
	 

	 	 

Terren S. Peizer, Chairman of the Board
	 	 
	 
	 	 	 	 
	MERGER SUBSIDIARY:	 	 
	 
	 	 	 	 
	NQCI ACQUISITION CORPORATION	 	 
	 
	 	 	 	 
	By:

	 	/s/ Terren S. Peizer	 	 
	 

	 	 

Terren S. Peizer
	 	 

35

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}]]